segment_id,segment_name,matched_code,match_type,matched_to,score
539,Melanom 20461.03,20461.03,EMBEDDED_IN_NAME,Melanom 20461.03,1.0
540,Nierenzellkarzinom (RCC) 20461.10,20461.10,EMBEDDED_IN_NAME,Nierenzellkarzinom (RCC) 20461.10,1.0
541,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.11,20461.11,EMBEDDED_IN_NAME,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.11,1.0
542,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,20461.01,EMBEDDED_IN_NAME,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,1.0
543,Melanom 20461.02,20461.02,EMBEDDED_IN_NAME,Melanom 20461.02,1.0
544,Melanom adjuvant 20461.07,20461.07,EMBEDDED_IN_NAME,Melanom adjuvant 20461.07,1.0
545,Nierenzellkarzinom (RCC) 20461.04,20461.04,EMBEDDED_IN_NAME,Nierenzellkarzinom (RCC) 20461.04,1.0
546,Nierenzellkarzinom (RCC) 20461.10,20461.10,EMBEDDED_IN_NAME,Nierenzellkarzinom (RCC) 20461.10,1.0
547,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN) 20461.05,20461.05,EMBEDDED_IN_NAME,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN) 20461.05,1.0
548,Klassisches Hodgkin-Lymphom (cHL) 20461.06,20461.06,EMBEDDED_IN_NAME,Klassisches Hodgkin-Lymphom (cHL) 20461.06,1.0
549,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.08,20461.08,EMBEDDED_IN_NAME,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.08,1.0
550,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.11,20461.11,EMBEDDED_IN_NAME,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.11,1.0
551,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant 20461.09,20461.09,EMBEDDED_IN_NAME,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant 20461.09,1.0
577,Melanom 20461.03,20461.03,EMBEDDED_IN_NAME,Melanom 20461.03,1.0
578,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,20461.01,EMBEDDED_IN_NAME,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,1.0
579,Melanom 20461.02,20461.02,EMBEDDED_IN_NAME,Melanom 20461.02,1.0
580,Melanom 20461.03,20461.03,EMBEDDED_IN_NAME,Melanom 20461.03,1.0
581,Melanom adjuvant 20461.07,20461.07,EMBEDDED_IN_NAME,Melanom adjuvant 20461.07,1.0
582,Nierenzellkarzinom (RCC) 20461.04,20461.04,EMBEDDED_IN_NAME,Nierenzellkarzinom (RCC) 20461.04,1.0
583,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN) 20461.05,20461.05,EMBEDDED_IN_NAME,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN) 20461.05,1.0
584,Klassisches Hodgkin-Lymphom (cHL) 20461.06,20461.06,EMBEDDED_IN_NAME,Klassisches Hodgkin-Lymphom (cHL) 20461.06,1.0
585,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.08,20461.08,EMBEDDED_IN_NAME,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.08,1.0
586,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant 20461.09,20461.09,EMBEDDED_IN_NAME,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant 20461.09,1.0
587,MIUC adjuvant 20461.12,20461.12,EMBEDDED_IN_NAME,MIUC adjuvant 20461.12,1.0
616,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,20461.01,EMBEDDED_IN_NAME,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,1.0
617,Melanom 20461.02,20461.02,EMBEDDED_IN_NAME,Melanom 20461.02,1.0
618,Melanom 20461.03,20461.03,EMBEDDED_IN_NAME,Melanom 20461.03,1.0
619,Melanom adjuvant 20461.07,20461.07,EMBEDDED_IN_NAME,Melanom adjuvant 20461.07,1.0
620,Nierenzellkarzinom (RCC) 20461.04 ,20461.04,EMBEDDED_IN_NAME,Nierenzellkarzinom (RCC) 20461.04 ,1.0
621,Nierenzellkarzinom (RCC) 20461.10,20461.10,EMBEDDED_IN_NAME,Nierenzellkarzinom (RCC) 20461.10,1.0
622,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN) 20461.05,20461.05,EMBEDDED_IN_NAME,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN) 20461.05,1.0
623,Klassisches Hodgkin-Lymphom (cHL) 20461.06,20461.06,EMBEDDED_IN_NAME,Klassisches Hodgkin-Lymphom (cHL) 20461.06,1.0
624,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.08,20461.08,EMBEDDED_IN_NAME,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.08,1.0
625,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.11,20461.11,EMBEDDED_IN_NAME,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H 20461.11,1.0
626,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant 20461.09,20461.09,EMBEDDED_IN_NAME,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant 20461.09,1.0
627,MIUC adjuvant 20461.12,20461.12,EMBEDDED_IN_NAME,MIUC adjuvant 20461.12,1.0
628,Ösophageales Plattenepithelkarzinom (OSCC) 20461.13,20461.13,EMBEDDED_IN_NAME,Ösophageales Plattenepithelkarzinom (OSCC) 20461.13,1.0
629,Ösophageales Plattenepithelkarzinom (OSCC) 20461.14,20461.14,EMBEDDED_IN_NAME,Ösophageales Plattenepithelkarzinom (OSCC) 20461.14,1.0
1376,Melanom 20461.02,20461.02,EMBEDDED_IN_NAME,Melanom 20461.02,1.0
1377,Melanom 20461.03,20461.03,EMBEDDED_IN_NAME,Melanom 20461.03,1.0
1378,Melanom adjuvant 20461.07,20461.07,EMBEDDED_IN_NAME,Melanom adjuvant 20461.07,1.0
1906,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,20461.01,EMBEDDED_IN_NAME,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,1.0
1985,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,20461.01,EMBEDDED_IN_NAME,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,1.0
1986,Melanom 20461.02,20461.02,EMBEDDED_IN_NAME,Melanom 20461.02,1.0
1987,Melanom 20461.03,20461.03,EMBEDDED_IN_NAME,Melanom 20461.03,1.0
1988,Melanom adjuvant 20461.07,20461.07,EMBEDDED_IN_NAME,Melanom adjuvant 20461.07,1.0
1989,Nierenzellkarzinom (RCC) 20461.04 ,20461.04,EMBEDDED_IN_NAME,Nierenzellkarzinom (RCC) 20461.04 ,1.0
1990,Nierenzellkarzinom (RCC) 20461.10,20461.10,EMBEDDED_IN_NAME,Nierenzellkarzinom (RCC) 20461.10,1.0
1991,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN) 20461.05,20461.05,EMBEDDED_IN_NAME,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN) 20461.05,1.0
1992,Klassisches Hodgkin-Lymphom (cHL) 20461.06,20461.06,EMBEDDED_IN_NAME,Klassisches Hodgkin-Lymphom (cHL) 20461.06,1.0
1993,Kolorektales Karzinom (CRC) mit dMMR/MSI-H 20461.08,20461.08,EMBEDDED_IN_NAME,Kolorektales Karzinom (CRC) mit dMMR/MSI-H 20461.08,1.0
1994,Kolorektales Karzinom (CRC) mit dMMR/MSI-H 20461.11,20461.11,EMBEDDED_IN_NAME,Kolorektales Karzinom (CRC) mit dMMR/MSI-H 20461.11,1.0
1995,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant 20461.09,20461.09,EMBEDDED_IN_NAME,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant 20461.09,1.0
1996,Muskel-invasives Urothelkarzinom (MIUC) adjuvant 20461.12,20461.12,EMBEDDED_IN_NAME,Muskel-invasives Urothelkarzinom (MIUC) adjuvant 20461.12,1.0
1997,Ösophageales Plattenepithelkarzinom (OSCC) 20461.13,20461.13,EMBEDDED_IN_NAME,Ösophageales Plattenepithelkarzinom (OSCC) 20461.13,1.0
1998,Ösophageales Plattenepithelkarzinom (OSCC) 20461.14,20461.14,EMBEDDED_IN_NAME,Ösophageales Plattenepithelkarzinom (OSCC) 20461.14,1.0
1999,Malignes pleurales Mesotheliom (MPM) 20461.15,20461.15,EMBEDDED_IN_NAME,Malignes pleurales Mesotheliom (MPM) 20461.15,1.0
2000,"Adenokarzinom des Magens, des gastroösophagealen Übergangs oder des distalen Ösophagus (GC/GEJC/OC) 20461.16",20461.16,EMBEDDED_IN_NAME,"Adenokarzinom des Magens, des gastroösophagealen Übergangs oder des distalen Ösophagus (GC/GEJC/OC) 20461.16",1.0
2150,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.17,20461.17,EMBEDDED_IN_NAME,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.17,1.0
2223,Renale Anämie bei Niereninsuffizienz: 17807.01,17807.01,EMBEDDED_IN_NAME,Renale Anämie bei Niereninsuffizienz: 17807.01,1.0
2263,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,20461.01,EMBEDDED_IN_NAME,Nicht-kleinzelliges Lungenkarzinom (NSCLC) 20461.01,1.0
2264,Melanom 20461.02,20461.02,EMBEDDED_IN_NAME,Melanom 20461.02,1.0
2265,Melanom 20461.03,20461.03,EMBEDDED_IN_NAME,Melanom 20461.03,1.0
2266,Melanom adjuvant 20461.07,20461.07,EMBEDDED_IN_NAME,Melanom adjuvant 20461.07,1.0
2267,Nierenzellkarzinom (RCC) 20461.04 ,20461.04,EMBEDDED_IN_NAME,Nierenzellkarzinom (RCC) 20461.04 ,1.0
2268,Nierenzellkarzinom (RCC) 20461.10,20461.10,EMBEDDED_IN_NAME,Nierenzellkarzinom (RCC) 20461.10,1.0
2269,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN) 20461.05,20461.05,EMBEDDED_IN_NAME,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN) 20461.05,1.0
2270,Klassisches Hodgkin-Lymphom (cHL) 20461.06,20461.06,EMBEDDED_IN_NAME,Klassisches Hodgkin-Lymphom (cHL) 20461.06,1.0
2271,Kolorektales Karzinom (CRC) mit dMMR/MSI-H 20461.08,20461.08,EMBEDDED_IN_NAME,Kolorektales Karzinom (CRC) mit dMMR/MSI-H 20461.08,1.0
2272,Kolorektales Karzinom (CRC) mit dMMR/MSI-H 20461.11,20461.11,EMBEDDED_IN_NAME,Kolorektales Karzinom (CRC) mit dMMR/MSI-H 20461.11,1.0
2273,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant 20461.09,20461.09,EMBEDDED_IN_NAME,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant 20461.09,1.0
2274,Muskel-invasives Urothelkarzinom (MIUC) adjuvant 20461.12,20461.12,EMBEDDED_IN_NAME,Muskel-invasives Urothelkarzinom (MIUC) adjuvant 20461.12,1.0
2275,Ösophageales Plattenepithelkarzinom (OSCC) 20461.13,20461.13,EMBEDDED_IN_NAME,Ösophageales Plattenepithelkarzinom (OSCC) 20461.13,1.0
2276,Ösophageales Plattenepithelkarzinom (OSCC) 20461.14,20461.14,EMBEDDED_IN_NAME,Ösophageales Plattenepithelkarzinom (OSCC) 20461.14,1.0
2277,Malignes pleurales Mesotheliom (MPM) 20461.15,20461.15,EMBEDDED_IN_NAME,Malignes pleurales Mesotheliom (MPM) 20461.15,1.0
2278,"Adenokarzinom des Magens, des gastroösophagealen Übergangs oder des distalen Ösophagus (GC/GEJC/OC) 20461.16",20461.16,EMBEDDED_IN_NAME,"Adenokarzinom des Magens, des gastroösophagealen Übergangs oder des distalen Ösophagus (GC/GEJC/OC) 20461.16",1.0
14,Tumornekrosefaktor-Rezeptor-assoziiertes periodisches Syndrom (TRAPS):,19119.03,NORMALIZED_MATCH,same dossier 19119,1.0
15,Hyperimmunglobulin-D-Syndrom (HIDS)/Mevalonatkinasedefizienz (MKD):,19119.04,NORMALIZED_MATCH,same dossier 19119,1.0
16,Familiäres Mittelmeerfieber (FMF):,19119.05,NORMALIZED_MATCH,same dossier 19119,1.0
19,Tumornekrosefaktor-Rezeptor-assoziiertes periodisches Syndrom (TRAPS):,19119.03,NORMALIZED_MATCH,same dossier 19119,1.0
20,Hyperimmunglobulin-D-Syndrom (HIDS)/Mevalonatkinasedefizienz (MKD):,19119.04,NORMALIZED_MATCH,same dossier 19119,1.0
21,Familiäres Mittelmeerfieber (FMF):,19119.05,NORMALIZED_MATCH,same dossier 19119,1.0
23,1L NSCLC,20416.01,NORMALIZED_CROSS,ind_part .01 from 20791.01,0.95
26,1L NSCLC,20416.01,NORMALIZED_CROSS,ind_part .01 from 20791.01,0.95
33,1L NSCLC,20416.01,NORMALIZED_CROSS,ind_part .01 from 20791.01,0.95
52,1L NSCLC,20416.01,NORMALIZED_CROSS,ind_part .01 from 20791.01,0.95
70,1L NSCLC,20416.01,NORMALIZED_CROSS,ind_part .01 from 20791.01,0.95
76,Melanom adjuvant,20461.02,NORMALIZED_CROSS,ind_part .02 from 20484.02,0.95
77,Melanom adjuvant,20416.02,NORMALIZED_CROSS,ind_part .02 from 20484.02,0.95
90,Kyprolis in Kombination mit Lenalidomid und Dexamethason (KRd),20481.06,NORMALIZED_MATCH,same dossier 20481,1.0
94,Colitis ulcerosa:,20037.04,NORMALIZED_CROSS,ind_part .04 from 20752.04,0.95
95,Psoriasis Arthritis:,20037.02,NORMALIZED_CROSS,ind_part .02 from 21476.02,0.95
98,Ovarialkarzinom nach Erstlinienchemotherapie,20852.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
106,Hämatologie:,20815.01,NORMALIZED_CROSS,ind_part .01 from 17079.01,0.95
107,Autoimmunerkrankungen:,20815.02,NORMALIZED_CROSS,ind_part .02 from 17079.02,0.95
122,Plaque-Psoriasis,19301.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
123,Psoriasis-Arthritis,19301.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
124,Morbus Crohn,19301.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
125,Colitis ulcerosa,19301.04,NORMALIZED_CROSS,ind_part .04 from 20752.04,0.95
126,Plaque-Psoriasis,20638.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
127,Psoriasis-Arthritis,20638.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
128,Morbus Crohn,20638.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
129,Colitis ulcerosa,20638.04,NORMALIZED_CROSS,ind_part .04 from 20752.04,0.95
130,Plaque-Psoriasis,20717.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
131,Psoriasis-Arthritis,20717.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
132,Morbus Crohn,20717.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
133,Colitis ulcerosa,20717.04,NORMALIZED_CROSS,ind_part .04 from 20752.04,0.95
182,Tumornekrosefaktor-Rezeptor-assoziiertes periodisches Syndrom (TRAPS):,19119.03,NORMALIZED_MATCH,same dossier 19119,1.0
183,Hyperimmunglobulin-D-Syndrom (HIDS)/Mevalonatkinasedefizienz (MKD):,19119.04,NORMALIZED_MATCH,same dossier 19119,1.0
184,Familiäres Mittelmeerfieber (FMF):,19119.05,NORMALIZED_MATCH,same dossier 19119,1.0
190,Psoriasis-Arthritis:,19300.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
194,Psoriasis-Arthritis:,19313.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
207,3L Primäres mediastinales grosszelliges B-Zell-Lymphom (rrPMBCL) (Monotherapie) KN170 ,20416.12,NORMALIZED_MATCH,same dossier 20416,1.0
227,Plaque-Psoriasis,20752.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
229,Plaque-Psoriasis,21007.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
263,Plaque-Psoriasis,19301.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
264,Plaque-Psoriasis,20638.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
265,Plaque-Psoriasis,20717.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
313,Plaque-Psoriasis:,20900.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
315,Morbus Crohn,20458.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
318,Schwere Plaque-Psoriasis,20458.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
319,Psoriasis Arthritis,20458.02,NORMALIZED_CROSS,ind_part .02 from 21476.02,0.95
345,Morbus Crohn,17463.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
348,Schwere Plaque-Psoriasis,17463.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
349,Psoriasis Arthritis,17463.02,NORMALIZED_CROSS,ind_part .02 from 21476.02,0.95
351,Morbus Crohn,20402.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
354,Schwere Plaque-Psoriasis,20402.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
355,Psoriasis Arthritis,20402.02,NORMALIZED_CROSS,ind_part .02 from 21476.02,0.95
356,Schwere Plaque-Psoriasis:,20922.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
359,Plaque-Psoriasis,19301.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
371,Atopische Dermatitis – Erwachsene,21258.01,NORMALIZED_CROSS,ind_part .01 from 20819.01,0.95
372,Atopische Dermatitis - Jugendliche Patienten,21258.02,NORMALIZED_CROSS,ind_part .02 from 20819.02,0.95
380,Melanom adjuvant,20461.02,NORMALIZED_CROSS,ind_part .02 from 20484.02,0.95
387,Psoriasis-Arthritis,21028.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
389,AL-Amyloidose,21150.04,NORMALIZED_MATCH,same dossier 21150,1.0
399,Melanom adjuvant,20461.02,NORMALIZED_CROSS,ind_part .02 from 20484.02,0.95
406,Ovarialkarzinom nach Erstlinienchemotherapie,20852.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
407,Monotherapie,20852.01,NORMALIZED_CROSS,ind_part .01 from 20589.01,0.95
408,Ovarialkarzinom nach Erstlinienchemotherapie,20852.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
414,Melanom adjuvant,20461.02,NORMALIZED_CROSS,ind_part .02 from 20484.02,0.95
420,Ovarialkarzinom nach Erstlinienchemotherapie,21090.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
423,Weitere Indikationen,17354.02,NORMALIZED_MATCH,same dossier 17354,1.0
425,Weitere Indikationen,21304.02,NORMALIZED_MATCH,same dossier 21304,1.0
427,Weitere Indikationen,21087.02,NORMALIZED_MATCH,same dossier 21087,1.0
429,Weitere Indikationen,21109.02,NORMALIZED_CROSS,ind_part .02 from 17354.02,0.95
435,Weitere Indikationen,20966.02,NORMALIZED_MATCH,same dossier 20966,1.0
457,Weitere Indikationen,21018.02,NORMALIZED_MATCH,same dossier 21018,1.0
494,HCC ,20641.03,NORMALIZED_MATCH,same dossier 20641,1.0
502,Ovarialkarzinom nach Erstlinienchemotherapie,21090.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
555,Behandlung von Erwachsenen mit paroxysmaler nächtlicher Hämoglobinurie (PNH),21024.01,NORMALIZED_CROSS,ind_part .01 from 21557.01,0.95
589,"Morbus Waldenström (MW, Monotherapie)",21365.05,NORMALIZED_CROSS,ind_part .05 from 21011.05,0.95
597,Colitis ulcerosa,19301.04,NORMALIZED_CROSS,ind_part .04 from 20752.04,0.95
598,Plaque-Psoriasis,20638.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
599,Colitis ulcerosa,20638.04,NORMALIZED_CROSS,ind_part .04 from 20752.04,0.95
600,Plaque-Psoriasis,20717.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
601,Colitis ulcerosa,20717.04,NORMALIZED_CROSS,ind_part .04 from 20752.04,0.95
636,Morbus Crohn,21322.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
644,Psoriasis-Arthritis,21203.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
648,Schwere Plaque-Psoriasis,21203.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
652,Psoriasis-Arthritis,21266.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
656,Schwere Plaque-Psoriasis,21266.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
662,Psoriasis-Arthritis,20992.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
666,Schwere Plaque-Psoriasis,20992.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
670,Psoriasis-Arthritis,21009.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
674,Schwere Plaque-Psoriasis,21009.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
682,Psoriasis-Arthritis,21453.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
686,Schwere Plaque-Psoriasis,21453.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
690,Psoriasis-Arthritis,21452.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
694,Schwere Plaque-Psoriasis,21452.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
698,Psoriasis-Arthritis ,21095.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
702,Schwere Plaque-Psoriasis ,21095.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
706,Psoriasis-Arthritis ,21095.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
710,Schwere Plaque-Psoriasis ,21095.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
714,Psoriasis-Arthritis ,21095.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
718,Schwere Plaque-Psoriasis ,21095.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
724,Psoriasis-Arthritis ,18538.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
728,Schwere Plaque-Psoriasis ,18538.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
732,Psoriasis-Arthritis ,17903.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
736,Schwere Plaque-Psoriasis ,17903.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
742,Psoriasis-Arthritis,20968.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
746,Schwere Plaque-Psoriasis,20968.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
750,Psoriasis-Arthritis,20969.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
754,Schwere Plaque-Psoriasis,20969.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
758,Psoriasis-Arthritis ,21086.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
762,Schwere Plaque-Psoriasis ,21086.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
766,Psoriasis-Arthritis ,21086.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
770,Schwere Plaque-Psoriasis ,21086.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
774,Psoriasis-Arthritis ,21086.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
778,Schwere Plaque-Psoriasis ,21086.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
782,Psoriasis-Arthritis,21076.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
786,Schwere Plaque-Psoriasis,21076.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
790,Psoriasis-Arthritis,21079.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
794,Schwere Plaque-Psoriasis,21079.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
800,Psoriasis-Arthritis,20992.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
804,Schwere Plaque-Psoriasis,20992.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
808,Psoriasis-Arthritis,21009.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
812,Schwere Plaque-Psoriasis,21009.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
815,Medulläres Schilddrüsenkarzinom mit RET-Mutation:,21321.02,NORMALIZED_MATCH,same dossier 21321,1.0
821,Schwere Plaque-Psoriasis:,20922.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
822,Psoriasis-Arthritis:,20922.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
827,Psoriasis-Arthritis,20992.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
831,Schwere Plaque-Psoriasis,20992.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
835,Psoriasis-Arthritis,21009.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
839,Schwere Plaque-Psoriasis,21009.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
845,Tumornekrosefaktor-Rezeptor-assoziiertes periodisches Syndrom (TRAPS):,19119.03,NORMALIZED_MATCH,same dossier 19119,1.0
846,Hyperimmunglobulin-D-Syndrom (HIDS)/Mevalonatkinasedefizienz (MKD):,19119.04,NORMALIZED_MATCH,same dossier 19119,1.0
847,Familiäres Mittelmeerfieber (FMF):,19119.05,NORMALIZED_MATCH,same dossier 19119,1.0
878,Plaque-Psoriasis,21476.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
879,Plaque-Psoriasis,21477.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
880,"Morbus Waldenström (MW, Monotherapie)",21365.05,NORMALIZED_CROSS,ind_part .05 from 21011.05,0.95
921,Colitis ulcerosa:,20037.04,NORMALIZED_CROSS,ind_part .04 from 20752.04,0.95
922,Psoriasis Arthritis:,20037.02,NORMALIZED_CROSS,ind_part .02 from 21476.02,0.95
930,Psoriasis-Arthritis,21203.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
934,Schwere Plaque-Psoriasis,21203.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
938,Psoriasis-Arthritis,21266.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
942,Schwere Plaque-Psoriasis,21266.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
946,Psoriasis-Arthritis,20992.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
950,Schwere Plaque-Psoriasis,20992.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
954,Psoriasis-Arthritis,21009.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
958,Schwere Plaque-Psoriasis,21009.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
964,Psoriasis-Arthritis,21453.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
968,Schwere Plaque-Psoriasis,21453.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
972,Psoriasis-Arthritis,21452.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
976,Schwere Plaque-Psoriasis,21452.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
980,Psoriasis-Arthritis ,21095.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
984,Schwere Plaque-Psoriasis ,21095.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
988,Psoriasis-Arthritis ,21095.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
992,Schwere Plaque-Psoriasis ,21095.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
996,Psoriasis-Arthritis ,21095.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1000,Schwere Plaque-Psoriasis ,21095.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1004,Psoriasis-Arthritis ,18538.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1008,Schwere Plaque-Psoriasis ,18538.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1012,Psoriasis-Arthritis ,17903.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1016,Schwere Plaque-Psoriasis ,17903.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1020,Psoriasis-Arthritis,20968.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1024,Schwere Plaque-Psoriasis,20968.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1028,Psoriasis-Arthritis,20969.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1032,Schwere Plaque-Psoriasis,20969.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1036,Psoriasis-Arthritis ,21086.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1040,Schwere Plaque-Psoriasis ,21086.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1044,Psoriasis-Arthritis ,21086.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1048,Schwere Plaque-Psoriasis ,21086.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1052,Psoriasis-Arthritis ,21086.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1056,Schwere Plaque-Psoriasis ,21086.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1060,Psoriasis-Arthritis,21076.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1064,Schwere Plaque-Psoriasis,21076.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1068,Psoriasis-Arthritis,21079.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1072,Schwere Plaque-Psoriasis,21079.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1093,Ovarialkarzinom nach Erstlinienchemotherapie,20852.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
1094,Monotherapie,20852.01,NORMALIZED_CROSS,ind_part .01 from 20589.01,0.95
1095,Ovarialkarzinom nach Erstlinienchemotherapie,20852.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
1115,Psoriasis-Arthritis ,21479.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1119,Schwere Plaque-Psoriasis ,21479.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1123,Psoriasis-Arthritis ,21480.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1127,Schwere Plaque-Psoriasis ,21480.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1165,Morbus Crohn,21536.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
1168,Schwere Plaque-Psoriasis,21536.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1169,Psoriasis Arthritis,21536.02,NORMALIZED_CROSS,ind_part .02 from 21476.02,0.95
1182,Ovarialkarzinom nach Erstlinienchemotherapie,21090.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
1205,Morbus Crohn,21606.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
1208,Schwere Plaque-Psoriasis,21606.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1209,Psoriasis Arthritis,21606.02,NORMALIZED_CROSS,ind_part .02 from 21476.02,0.95
1210,Hämatologie:,20820.01,NORMALIZED_CROSS,ind_part .01 from 17079.01,0.95
1211,Autoimmunerkrankungen:,20820.02,NORMALIZED_CROSS,ind_part .02 from 17079.02,0.95
1213,Hämatologie:,20815.01,NORMALIZED_CROSS,ind_part .01 from 17079.01,0.95
1214,Autoimmunerkrankungen:,20815.02,NORMALIZED_CROSS,ind_part .02 from 17079.02,0.95
1285,Behandlung von Erwachsenen mit paroxysmaler nächtlicher Hämoglobinurie (PNH),21024.01,NORMALIZED_CROSS,ind_part .01 from 21557.01,0.95
1294,"Morbus Waldenström (MW, Monotherapie)",21365.05,NORMALIZED_CROSS,ind_part .05 from 21011.05,0.95
1304,Schwere Plaque-Psoriasis:,20900.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1305,Schwere Plaque-Psoriasis:,20900.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1312,Psoriasis-Arthritis,21028.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1333,Tumornekrosefaktor-Rezeptor-assoziiertes periodisches Syndrom (TRAPS):,19119.03,NORMALIZED_MATCH,same dossier 19119,1.0
1334,Hyperimmunglobulin-D-Syndrom (HIDS)/Mevalonatkinasedefizienz (MKD):,19119.04,NORMALIZED_MATCH,same dossier 19119,1.0
1335,Familiäres Mittelmeerfieber (FMF):,19119.05,NORMALIZED_MATCH,same dossier 19119,1.0
1345,Morbus Crohn (nur 360 mg und 600 mg),20922.03,NORMALIZED_MATCH,same dossier 21718,1.0
1346,Morbus Crohn (nur 360 mg und 600 mg),21719.03,NORMALIZED_CROSS,ind_part .03 from 20922.03,0.95
1387,Patienten mit Hämophilie A mit Hemmkörpern,21692.01,NORMALIZED_CROSS,ind_part .01 from 20818.01,0.95
1390,Autoimmunerkrankungen:,20820.02,NORMALIZED_CROSS,ind_part .02 from 17079.02,0.95
1395,Autoimmunerkrankungen:,20815.02,NORMALIZED_CROSS,ind_part .02 from 17079.02,0.95
1409,Psoriasis-Arthritis,21203.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1413,Schwere Plaque-Psoriasis,21203.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1418,Psoriasis-Arthritis,21266.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1422,Schwere Plaque-Psoriasis,21266.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1430,Psoriasis-Arthritis,20992.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1434,Schwere Plaque-Psoriasis,20992.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1439,Psoriasis-Arthritis,21009.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1443,Schwere Plaque-Psoriasis,21009.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1445,Ovarialkarzinom nach Erstlinienchemotherapie,18082.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
1456,Ovarialkarzinom nach Erstlinienchemotherapie,21264.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
1481,Psoriasis-Arthritis,21453.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1485,Schwere Plaque-Psoriasis,21453.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1490,Psoriasis-Arthritis,21452.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1494,Schwere Plaque-Psoriasis,21452.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1499,Psoriasis-Arthritis ,21095.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1503,Schwere Plaque-Psoriasis ,21095.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1508,Psoriasis-Arthritis ,21095.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1512,Schwere Plaque-Psoriasis ,21095.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1517,Psoriasis-Arthritis ,21095.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1521,Schwere Plaque-Psoriasis ,21095.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1529,Psoriasis-Arthritis,20968.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1533,Schwere Plaque-Psoriasis,20968.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1538,Psoriasis-Arthritis,20969.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1542,Schwere Plaque-Psoriasis,20969.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1547,Psoriasis-Arthritis ,21086.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1551,Schwere Plaque-Psoriasis ,21086.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1556,Psoriasis-Arthritis ,21086.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1560,Schwere Plaque-Psoriasis ,21086.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1565,Psoriasis-Arthritis ,21086.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1569,Schwere Plaque-Psoriasis ,21086.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1577,Psoriasis-Arthritis,21076.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1581,Schwere Plaque-Psoriasis,21076.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1586,Psoriasis-Arthritis,21079.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1590,Schwere Plaque-Psoriasis,21079.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1594,Morbus Crohn,20458.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
1597,Schwere Plaque-Psoriasis,20458.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1598,Psoriasis Arthritis,20458.02,NORMALIZED_CROSS,ind_part .02 from 21476.02,0.95
1601,Ovarialkarzinom nach Erstlinienchemotherapie,21084.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
1611,Morbus Crohn,20402.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
1614,Schwere Plaque-Psoriasis,20402.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1615,Psoriasis Arthritis,20402.02,NORMALIZED_CROSS,ind_part .02 from 21476.02,0.95
1618,Morbus Crohn,21606.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
1621,Schwere Plaque-Psoriasis,21606.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1622,Psoriasis Arthritis,21606.02,NORMALIZED_CROSS,ind_part .02 from 21476.02,0.95
1632,Psoriasis-Arthritis ,21479.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1636,Schwere Plaque-Psoriasis ,21479.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1641,Psoriasis-Arthritis ,21480.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1645,Schwere Plaque-Psoriasis ,21480.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1651,Psoriasis-Arthritis,21203.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1655,Schwere Plaque-Psoriasis,21203.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1660,Psoriasis-Arthritis,21266.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1664,Schwere Plaque-Psoriasis,21266.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1672,Psoriasis-Arthritis,20992.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1676,Schwere Plaque-Psoriasis,20992.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1681,Psoriasis-Arthritis,21009.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1685,Schwere Plaque-Psoriasis,21009.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1688,Schwere Plaque-Psoriasis,20311.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1694,Schwere Plaque-Psoriasis,20311.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1699,Schwere Plaque-Psoriasis,20316.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1703,Schwere Plaque-Psoriasis,21385.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1720,Schwere Plaque-Psoriasis:,21753.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1725,Psoriasis-Arthritis,21076.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1729,Schwere Plaque-Psoriasis,21076.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1734,Psoriasis-Arthritis,21079.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1738,Schwere Plaque-Psoriasis,21079.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1742,Morbus Crohn,20458.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
1745,Schwere Plaque-Psoriasis,20458.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1746,Psoriasis Arthritis,20458.02,NORMALIZED_CROSS,ind_part .02 from 21476.02,0.95
1774,Ovarialkarzinom nach Erstlinienchemotherapie,21272.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
1778,Plaque-Psoriasis,19301.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
1779,Plaque-Psoriasis,20638.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
1780,Plaque-Psoriasis,20717.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
1781,Plaque-Psoriasis,21754.01,NORMALIZED_CROSS,ind_part .01 from 21652.01,0.95
1782,Psoriasis-Arthritis,21754.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1783,Morbus Crohn,21754.03,NORMALIZED_CROSS,ind_part .03 from 20752.03,0.95
1784,Colitis ulcerosa,21754.04,NORMALIZED_CROSS,ind_part .04 from 20752.04,0.95
1786,Ovarialkarzinom nach Erstlinienchemotherapie,21617.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
1795,Psoriasis-Arthritis ,21086.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1799,Schwere Plaque-Psoriasis ,21086.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1804,Psoriasis-Arthritis ,21086.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1808,Schwere Plaque-Psoriasis ,21086.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1833,Austausch Originalpräparat/Generikum,21157.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1834,Austausch Originalpräparat/Generikum,21387.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1835,Austausch Originalpräparat/Generikum,21032.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1836,Austausch Originalpräparat/Generikum,21035.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1837,Austausch Originalpräparat/Generikum,21309.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1840,Austausch Originalpräparat/Generikum,21398.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1842,Austausch Originalpräparat/Generikum,21377.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1843,Austausch Originalpräparat/Generikum,21420.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1844,Austausch Originalpräparat/Generikum,21312.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1845,Austausch Originalpräparat/Generikum,21384.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1846,Austausch Originalpräparat/Generikum,21626.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1848,Austausch Originalpräparat/Generikum,21381.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1849,Austausch Originalpräparat/Generikum,21379.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1850,Austausch Originalpräparat/Generikum,19852.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1851,Austausch Originalpräparat/Generikum,20351.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1852,Austausch Originalpräparat/Generikum,20051.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1855,Austausch Originalpräparat/Generikum,21262.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1856,Austausch Originalpräparat/Generikum,21263.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1857,Austausch Originalpräparat/Generikum,21251.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1858,Austausch Originalpräparat/Generikum,21256.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1859,Austausch Originalpräparat/Generikum,21263.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1860,Austausch Originalpräparat/Generikum,21352.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1861,Austausch Originalpräparat/Generikum,21243.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1862,Austausch Originalpräparat/Generikum,21773.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1864,Austausch Originalpräparat/Generikum,21805.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1865,Austausch Originalpräparat/Generikum,21806.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1907,Austausch Originalpräparat/Generikum,21263.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1908,Austausch Originalpräparat/Generikum,21251.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1909,Austausch Originalpräparat/Generikum,21256.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1910,Austausch Originalpräparat/Generikum,21263.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1911,Austausch Originalpräparat/Generikum,21352.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1912,Austausch Originalpräparat/Generikum,21243.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1944,Austausch Originalpräparat/Generikum,21262.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1945,Austausch Originalpräparat/Generikum,21251.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
1947,Hämatologie:,21862.01,NORMALIZED_CROSS,ind_part .01 from 17079.01,0.95
1948,Autoimmunerkrankungen:,21862.02,NORMALIZED_CROSS,ind_part .02 from 17079.02,0.95
1967,Psoriasis-Arthritis,20992.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1971,Schwere Plaque-Psoriasis,20992.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
1976,Psoriasis-Arthritis,21009.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
1980,Schwere Plaque-Psoriasis,21009.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
2001,Austausch Originalpräparat/Generikum,21880.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
2075,Psoriasis-Arthritis ,21095.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
2079,Schwere Plaque-Psoriasis ,21095.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
2084,Psoriasis-Arthritis ,21095.02,NORMALIZED_CROSS,ind_part .02 from 21327.02,0.95
2088,Schwere Plaque-Psoriasis ,21095.01,NORMALIZED_CROSS,ind_part .01 from 21327.01,0.95
2157,Behandlung von Erwachsenen mit paroxysmaler nächtlicher Hämoglobinurie (PNH),21024.01,NORMALIZED_CROSS,ind_part .01 from 21557.01,0.95
2162,"Morbus Waldenström (MW, Monotherapie)",21365.05,NORMALIZED_CROSS,ind_part .05 from 21011.05,0.95
2208,Austausch Originalpräparat/Generikum,22005.01,NORMALIZED_CROSS,ind_part .01 from 21423.01,0.95
2333,Ovarialkarzinom nach Erstlinienchemotherapie,21090.02,NORMALIZED_CROSS,ind_part .02 from 21597.02,0.95
28,Nicht-kleinzelliges Lungenkarzinom (NSCLC),20461.07,PIPE_PART_CROSS,ind_part .07 from 19520.07,0.9
30,Nierenzellkarzinom (RCC),20461.03,PIPE_PART_CROSS,ind_part .03 from 19520.03,0.9
42,Nicht-kleinzelliges Lungenkarzinom (NSCLC),20461.07,PIPE_PART_CROSS,ind_part .07 from 19520.07,0.9
45,Nierenzellkarzinom (RCC),20461.03,PIPE_PART_CROSS,ind_part .03 from 19520.03,0.9
58,"Indikationsübergreifende Limitatio (CRC, GIST und HCC)",20050.01,PIPE_PART_MATCH,same dossier 20050,0.95
59,Kolorektalkarzinom (CRC),20050.01,PIPE_PART_MATCH,same dossier 20050,0.95
60,Gastrointestinale Stromatumoren (GIST),20050.01,PIPE_PART_MATCH,same dossier 20050,0.95
61,Leberzellkarzinom (HCC),20050.01,PIPE_PART_MATCH,same dossier 20050,0.95
62,"Indikationsübergreifende Limitatio (CRC, GIST und HCC)",20050.01,PIPE_PART_MATCH,same dossier 20050,0.95
63,Kolorektalkarzinom (CRC),20050.01,PIPE_PART_MATCH,same dossier 20050,0.95
64,Gastrointestinale Stromatumoren (GIST),20050.01,PIPE_PART_MATCH,same dossier 20050,0.95
65,Leberzellkarzinom (HCC),20050.01,PIPE_PART_MATCH,same dossier 20050,0.95
67,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",19016.02,PIPE_PART_MATCH,same dossier 19016,0.95
71,Nicht-kleinzelliges Lungenkarzinom (NSCLC) ,20461.07,PIPE_PART_CROSS,ind_part .07 from 19520.07,0.9
73,Nierenzellkarzinom (RCC),20461.03,PIPE_PART_CROSS,ind_part .03 from 19520.03,0.9
110,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",19016.02,PIPE_PART_MATCH,same dossier 19016,0.95
118,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",19016.02,PIPE_PART_MATCH,same dossier 19016,0.95
149,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",19016.02,PIPE_PART_MATCH,same dossier 19016,0.95
223,"Kombination REVLIMID, Elotuzumab und Dexamethason",18541.08,KOMBI_NORMALIZED,same dossier 18541,0.9
226,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",19016.02,PIPE_PART_MATCH,same dossier 19016,0.95
358,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",19016.02,PIPE_PART_MATCH,same dossier 19016,0.95
378,Nicht-kleinzelliges Lungenkarzinom (NSCLC),20461.07,PIPE_PART_CROSS,ind_part .07 from 19520.07,0.9
381,Nierenzellkarzinom (RCC),20461.03,PIPE_PART_CROSS,ind_part .03 from 19520.03,0.9
400,Nierenzellkarzinom (RCC),20461.03,PIPE_PART_CROSS,ind_part .03 from 19520.03,0.9
409,Kombinationstherapie mit Bevacizumab,20852.02,PIPE_PART_MATCH,same dossier 20852,0.95
411,Nicht-kleinzelliges Lungenkarzinom (NSCLC),20461.07,PIPE_PART_CROSS,ind_part .07 from 19520.07,0.9
415,Nierenzellkarzinom (RCC),20461.03,PIPE_PART_CROSS,ind_part .03 from 19520.03,0.9
421,Kombinationstherapie mit Lynparza (Olaparib),21090.08,PIPE_PART_MATCH,same dossier 21090,0.95
422,HERCEPTIN in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,17354.01,PIPE_PART_MATCH,same dossier 17354,0.95
424,HERZUMA in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21304.01,PIPE_PART_MATCH,same dossier 21304,0.95
426,OGIVRI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21087.01,PIPE_PART_MATCH,same dossier 21087,0.95
428,OGIVRI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21109.01,PIPE_PART_CROSS,ind_part .01 from 21087.01,0.9
434,TRAZIMERA in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,20966.01,PIPE_PART_MATCH,same dossier 20966,0.95
443,AVASTIN in Kombination mit Atezolizumab (TECENTRIQ) zur Behandlung des inoperablen oder metastasierten hepatozellulären Karzinoms (HCC),18082.08,PIPE_PART_MATCH,same dossier 18082,0.95
447,Daratumumab in Kombination mit Lenalidomid und Dexamethason ,20589.02,KOMBI_NORMALIZED,same dossier 20589,0.9
451,Daratumumab in Kombination mit Lenalidomid und Dexamethason ,21150.02,KOMBI_NORMALIZED,same dossier 21150,0.9
456,KANJINTI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21018.01,PIPE_PART_MATCH,same dossier 21018,0.95
481,"Kombination LENALIDOMID-TEVA, Elotuzumab und Dexamethason",21379.08,KOMBI_CROSS,ind_part .08 from 18541.08,0.85
491,OYAVAS in Kombination mit Atezolizumab (TECENTRIQ) zur Behandlung des inoperablen oder metastasierten hepatozellulären Karzinoms (HCC),21272.08,PIPE_PART_MATCH,same dossier 21272,0.95
503,Kombinationstherapie mit Lynparza (Olaparib),21090.08,PIPE_PART_MATCH,same dossier 21090,0.95
504,ZIRABEV in Kombination mit Atezolizumab (TECENTRIQ) zur Behandlung des inoperablen oder metastasierten hepatozellulären Karzinoms (HCC),21090.09,PIPE_PART_MATCH,same dossier 21090,0.95
526,"Kombination LENALIDOMID-TEVA, Elotuzumab und Dexamethason",21379.08,KOMBI_CROSS,ind_part .08 from 18541.08,0.85
553,"Kombination REVLIMID, Elotuzumab und Dexamethason",18541.08,KOMBI_NORMALIZED,same dossier 18541,0.9
556,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",21024.02,PIPE_PART_CROSS,ind_part .02 from 19016.02,0.9
588,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",21024.02,PIPE_PART_CROSS,ind_part .02 from 19016.02,0.9
607,KYPROLIS in Kombination mit Daratumumab und Dexamethason (KDd),20481.02,PIPE_PART_MATCH,same dossier 20481,0.95
614,"Kombination LENALIDOMID-TEVA, Ixazomib und Dexamethason",21379.09,KOMBI_CROSS,ind_part .09 from 18541.09,0.85
633,"Kombination REVLIMID, Ixazomib und Dexamethason",18541.09,KOMBI_NORMALIZED,same dossier 18541,0.9
853,"Kombination REVLIMID, Elotuzumab und Dexamethason",18541.08,KOMBI_NORMALIZED,same dossier 18541,0.9
854,"Kombination REVLIMID, Ixazomib und Dexamethason",18541.09,KOMBI_NORMALIZED,same dossier 18541,0.9
882,HERCEPTIN in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,17354.01,PIPE_PART_MATCH,same dossier 17354,0.95
884,HERZUMA in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21304.01,PIPE_PART_MATCH,same dossier 21304,0.95
893,Kombination LENALIDOMID-TEVA und Tafasitamab,21379.11,KOMBI_CROSS,ind_part .11 from 18541.11,0.85
901,OGIVRI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21087.01,PIPE_PART_MATCH,same dossier 21087,0.95
903,OGIVRI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21109.01,PIPE_PART_CROSS,ind_part .01 from 21087.01,0.9
918,TRAZIMERA in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,20966.01,PIPE_PART_MATCH,same dossier 20966,0.95
1074,KANJINTI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21018.01,PIPE_PART_MATCH,same dossier 21018,0.95
1096,Kombinationstherapie mit Bevacizumab,20852.02,PIPE_PART_MATCH,same dossier 20852,0.95
1136,AVASTIN in Kombination mit Atezolizumab (TECENTRIQ) zur Behandlung des inoperablen oder metastasierten hepatozellulären Karzinoms (HCC),18082.08,PIPE_PART_MATCH,same dossier 18082,0.95
1163,OYAVAS in Kombination mit Atezolizumab (TECENTRIQ) zur Behandlung des inoperablen oder metastasierten hepatozellulären Karzinoms (HCC),21272.08,PIPE_PART_MATCH,same dossier 21272,0.95
1183,Kombinationstherapie mit Lynparza (Olaparib),21090.08,PIPE_PART_MATCH,same dossier 21090,0.95
1184,ZIRABEV in Kombination mit Atezolizumab (TECENTRIQ) zur Behandlung des inoperablen oder metastasierten hepatozellulären Karzinoms (HCC),21090.09,PIPE_PART_MATCH,same dossier 21090,0.95
1258,HERCEPTIN in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,17354.01,PIPE_PART_MATCH,same dossier 17354,0.95
1259,HERZUMA in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21304.01,PIPE_PART_MATCH,same dossier 21304,0.95
1262,KANJINTI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21018.01,PIPE_PART_MATCH,same dossier 21018,0.95
1265,OGIVRI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21087.01,PIPE_PART_MATCH,same dossier 21087,0.95
1266,OGIVRI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21109.01,PIPE_PART_CROSS,ind_part .01 from 21087.01,0.9
1269,TRAZIMERA in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,20966.01,PIPE_PART_MATCH,same dossier 20966,0.95
1278,ZERCEPAC in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21605.01,PIPE_PART_MATCH,same dossier 21605,0.95
1286,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",21024.02,PIPE_PART_CROSS,ind_part .02 from 19016.02,0.9
1317,Hodgkin-Lymphom (HL),19989.01,PIPE_PART_MATCH,same dossier 19989,0.95
1318,"HL (Stadium IV), Kombinationstherapie (mit Preismodell)",19989.01,PIPE_PART_MATCH,same dossier 19989,0.95
1319,Hodgkin-Lymphom (HL),19989.01,PIPE_PART_MATCH,same dossier 19989,0.95
1320,"Rezidiviertes oder refraktäres HL, Monotherapie (mit Preismodell)",19989.02,PIPE_PART_MATCH,same dossier 19989,0.95
1321,Periphere T-Zell-Lymphome (PTCL),19989.03,PIPE_PART_MATCH,same dossier 19989,0.95
1322,"PTCL, Kombinationstherapie (mit Preismodell)",19989.03,PIPE_PART_MATCH,same dossier 19989,0.95
1323,Periphere T-Zell-Lymphome (PTCL),19989.03,PIPE_PART_MATCH,same dossier 19989,0.95
1324,"Rezidiviertes oder refraktäres sALCL, Monotherapie (mit Preismodell)",19989.04,PIPE_PART_MATCH,same dossier 19989,0.95
1357,LENALIDOMID ACCORD in Kombination mit DARZALEX / DARZALEX SC und Dexamethason,21398.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1359,LENALIDOMID BMS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason,21377.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1361,LENALIDOMID DEVATIS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason,21420.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1363,LENALIDOMID SANDOZ in Kombination mit DARZALEX / DARZALEX SC und Dexamethason,21312.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1365,LENALIDOMID SPIRIG HC in Kombination mit DARZALEX / DARZALEX SC und Dexamethason,21384.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1367,LENALIDOMID VIATRIS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason,21626.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1369,LENALIDOMID ZENTIVA in Kombination mit DARZALEX / DARZALEX SC und Dexamethason,21381.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1370,Kombination LENALIDOMID-TEVA und Tafasitamab,21379.11,KOMBI_CROSS,ind_part .11 from 18541.11,0.85
1371,LENALIDOMID-TEVA in Kombination mit DARZALEX / DARZALEX SC und Dexamethason,21379.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1446,Kombinationstherapie mit Lynparza (Olaparib),18082.09,PIPE_PART_MATCH,same dossier 18082,0.95
1457,Kombinationstherapie mit Lynparza (Olaparib),21264.09,PIPE_PART_MATCH,same dossier 21264,0.95
1602,Kombinationstherapie mit Lynparza (Olaparib),21084.09,PIPE_PART_MATCH,same dossier 21084,0.95
1748,LENALIDOMID ACCORD in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21398.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1749,LENALIDOMID ACCORD in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (1L),21398.13,KOMBI_CROSS,ind_part .13 from 18541.13,0.85
1751,LENALIDOMID BMS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21377.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1752,LENALIDOMID BMS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (1L),21377.13,KOMBI_CROSS,ind_part .13 from 18541.13,0.85
1753,LENALIDOMID ACCORD in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (1L),21377.13,KOMBI_CROSS,ind_part .13 from 18541.13,0.85
1755,LENALIDOMID DEVATIS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21420.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1756,LENALIDOMID DEVATIS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (1L),21420.13,KOMBI_CROSS,ind_part .13 from 18541.13,0.85
1758,LENALIDOMID SANDOZ in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21312.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1759,LENALIDOMID SANDOZ in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (1L),21312.13,KOMBI_CROSS,ind_part .13 from 18541.13,0.85
1761,LENALIDOMID SPIRIG HC in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21384.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1762,LENALIDOMID SPIRIG HC in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (1L),21384.13,KOMBI_CROSS,ind_part .13 from 18541.13,0.85
1763,LENALIDOMID VIATRIS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21626.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1764,LENALIDOMID VIATRIS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (1L),21626.13,KOMBI_CROSS,ind_part .13 from 18541.13,0.85
1765,LENALIDOMID ACCORD in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21626.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1767,LENALIDOMID ZENTIVA in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21381.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1768,LENALIDOMID ZENTIVA in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (1L),21381.13,KOMBI_CROSS,ind_part .13 from 18541.13,0.85
1769,Kombination LENALIDOMID-TEVA und Tafasitamab,21379.11,KOMBI_CROSS,ind_part .11 from 18541.11,0.85
1770,LENALIDOMID-TEVA in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21379.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1771,LENALIDOMID-TEVA in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (1L),21379.13,KOMBI_CROSS,ind_part .13 from 18541.13,0.85
1773,Oyavas in Kombination mit Atezolizumab (TECENTRIQ) zur Behandlung des inoperablen oder metastasierten hepatozellulären Karzinoms (HCC),21272.08,PIPE_PART_MATCH,same dossier 21272,0.95
1775,Kombinationstherapie mit Lynparza (Olaparib),21272.09,PIPE_PART_MATCH,same dossier 21272,0.95
1787,Kombinationstherapie mit Lynparza (Olaparib),21617.09,PIPE_PART_MATCH,same dossier 21617,0.95
1790,POMALIDOMID SANDOZ in Kombination mit Daratumumab und Dexamethason (2L+),21773.03,KOMBI_CROSS,ind_part .03 from 20221.03,0.85
1791,POMALIDOMID SANDOZ in Kombination mit Isatuximab und Dexamethason,21773.04,KOMBI_CROSS,ind_part .04 from 20221.04,0.85
1811,POMALIDOMID ZENTIVA in Kombination mit Daratumumab und Dexamethason (2L+),21806.03,KOMBI_CROSS,ind_part .03 from 20221.03,0.85
1812,POMALIDOMID ZENTIVA in Kombination mit Isatuximab und Dexamethason,21806.04,KOMBI_CROSS,ind_part .04 from 20221.04,0.85
1813,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",19016.02,PIPE_PART_MATCH,same dossier 19016,0.95
1817,POMALIDOMID SPIRIG HC in Kombination mit Daratumumab und Dexamethason (2L+),21805.03,KOMBI_CROSS,ind_part .03 from 20221.03,0.85
1818,POMALIDOMID SPIRIG HC in Kombination mit Isatuximab und Dexamethason,21805.04,KOMBI_CROSS,ind_part .04 from 20221.04,0.85
1841,LENALIDOMID VIATRIS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21398.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1847,LENALIDOMID VIATRIS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21626.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
1863,POMALIDOMID SANDOZ in Kombination mit Daratumumab und Dexamethason (2L+),21773.03,KOMBI_CROSS,ind_part .03 from 20221.03,0.85
1904,Kombination LENALIDOMID-TEVA und Tafasitamab,21379.11,KOMBI_CROSS,ind_part .11 from 18541.11,0.85
1929,4-24 Monate:,20145.01,PIPE_PART_MATCH,same dossier 20145,0.95
1930,2-11 Jahre:,20145.01,PIPE_PART_MATCH,same dossier 20145,0.95
1931,Ab 12 Jahren:,20145.01,PIPE_PART_MATCH,same dossier 20145,0.95
1932,4-24 Monate:,21563.01,PIPE_PART_MATCH,same dossier 21563,0.95
1933,2-11 Jahre:,21563.01,PIPE_PART_MATCH,same dossier 21563,0.95
1934,Ab 12 Jahren:,21563.01,PIPE_PART_MATCH,same dossier 21563,0.95
1935,4-24 Monate:,20543.01,PIPE_PART_MATCH,same dossier 20543,0.95
1936,2-11 Jahre:,20543.01,PIPE_PART_MATCH,same dossier 20543,0.95
1937,Ab 12 Jahren:,20543.01,PIPE_PART_MATCH,same dossier 20543,0.95
1938,4-24 Monate:,20543.01,PIPE_PART_MATCH,same dossier 20543,0.95
1939,2-11 Jahre:,20543.01,PIPE_PART_MATCH,same dossier 20543,0.95
1940,Ab 12 Jahren:,20543.01,PIPE_PART_MATCH,same dossier 20543,0.95
1941,4-24 Monate:,21561.01,PIPE_PART_MATCH,same dossier 21561,0.95
1942,2-11 Jahre:,21561.01,PIPE_PART_MATCH,same dossier 21561,0.95
1943,Ab 12 Jahren:,21561.01,PIPE_PART_MATCH,same dossier 21561,0.95
1951,4-24 Monate:,20914.01,PIPE_PART_MATCH,same dossier 20914,0.95
1952,2-11 Jahre:,20914.01,PIPE_PART_MATCH,same dossier 20914,0.95
1953,Ab 12 Jahren:,20914.01,PIPE_PART_MATCH,same dossier 20914,0.95
1955,4-24 Monate:,21144.01,PIPE_PART_MATCH,same dossier 21144,0.95
1956,2-11 Jahre:,21144.01,PIPE_PART_MATCH,same dossier 21144,0.95
1957,Ab 12 Jahren:,21144.01,PIPE_PART_MATCH,same dossier 21144,0.95
1958,4-24 Monate:,21144.01,PIPE_PART_MATCH,same dossier 21144,0.95
1959,2-11 Jahre:,21144.01,PIPE_PART_MATCH,same dossier 21144,0.95
1960,Ab 12 Jahren:,21144.01,PIPE_PART_MATCH,same dossier 21144,0.95
1961,4-24 Monate:,21777.01,PIPE_PART_MATCH,same dossier 21777,0.95
1962,2-11 Jahre:,21777.01,PIPE_PART_MATCH,same dossier 21777,0.95
1963,Ab 12 Jahren:,21777.01,PIPE_PART_MATCH,same dossier 21777,0.95
2002,"Kombination POMALIDOMID-TEVA, Elotuzumab und Dexamethason",21880.01,KOMBI_CROSS,ind_part .01 from 20221.01,0.85
2003,POMALIDOMID-TEVA in Kombination mit Daratumumab und Dexamethason (2L+),21880.03,KOMBI_CROSS,ind_part .03 from 20221.03,0.85
2004,POMALIDOMID-TEVA in Kombination mit Isatuximab und Dexamethason,21880.04,KOMBI_CROSS,ind_part .04 from 20221.04,0.85
2005,POMALIDOMID SANDOZ in Kombination mit Isatuximab und Dexamethason,21880.04,KOMBI_CROSS,ind_part .04 from 20221.04,0.85
2027,LENALIDOMID ACCORD in Kombination mit Elotuzumab und Dexamethason,21398.08,KOMBI_CROSS,ind_part .08 from 18541.08,0.85
2028,LENALIDOMID BMS in Kombination mit Elotuzumab und Dexamethason,21377.08,KOMBI_CROSS,ind_part .08 from 18541.08,0.85
2029,LENALIDOMID DEVATIS in Kombination mit Elotuzumab und Dexamethason,21420.08,KOMBI_CROSS,ind_part .08 from 18541.08,0.85
2030,LENALIDOMID SANDOZ in Kombination mit Elotuzumab und Dexamethason,21312.08,KOMBI_CROSS,ind_part .08 from 18541.08,0.85
2031,LENALIDOMID SPIRIG HC in Kombination mit Elotuzumab und Dexamethason,21384.08,KOMBI_CROSS,ind_part .08 from 18541.08,0.85
2032,LENALIDOMID VIATRIS in Kombination mit Elotuzumab und Dexamethason,21626.08,KOMBI_CROSS,ind_part .08 from 18541.08,0.85
2033,LENALIDOMID ZENTIVA in Kombination mit Elotuzumab und Dexamethason,21381.08,KOMBI_CROSS,ind_part .08 from 18541.08,0.85
2034,LENALIDOMID-TEVA in Kombination mit Elotuzumab und Dexamethason,21379.08,KOMBI_CROSS,ind_part .08 from 18541.08,0.85
2041,Melanom Kombinationstherapie,19520.02,PIPE_PART_MATCH,same dossier 19520,0.95
2042,Nierenzellkarzinom (RCC),19520.03,PIPE_PART_MATCH,same dossier 19520,0.95
2043,Kolorektales Karzinom (CRC) mit dMMR/MSI-H,19520.04,PIPE_PART_MATCH,same dossier 19520,0.95
2044,Ösophageales Plattenepithelkarzinom (OSCC),19520.05,PIPE_PART_MATCH,same dossier 19520,0.95
2045,Malignes pleurales Mesotheliom (MPM),19520.06,PIPE_PART_MATCH,same dossier 19520,0.95
2068,Vitiligo Erwachsene und Jugendliche ab 12 Jahren,21819.01,PIPE_PART_MATCH,same dossier 21819,0.95
2103,LENALIDOMID ACCORD in Kombination mit Ixazomib und Dexamethason,21398.09,KOMBI_CROSS,ind_part .09 from 18541.09,0.85
2104,LENALIDOMID BMS in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21377.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
2105,LENALIDOMID BMS in Kombination mit Ixazomib und Dexamethason,21377.09,KOMBI_CROSS,ind_part .09 from 18541.09,0.85
2106,LENALIDOMID DEVATIS in Kombination mit Ixazomib und Dexamethason,21420.09,KOMBI_CROSS,ind_part .09 from 18541.09,0.85
2107,LENALIDOMID SANDOZ in Kombination mit Ixazomib und Dexamethason,21312.09,KOMBI_CROSS,ind_part .09 from 18541.09,0.85
2108,LENALIDOMID SPIRIG HC in Kombination mit Ixazomib und Dexamethason,21384.09,KOMBI_CROSS,ind_part .09 from 18541.09,0.85
2109,LENALIDOMID VIATRIS in Kombination mit Ixazomib und Dexamethason,21626.09,KOMBI_CROSS,ind_part .09 from 18541.09,0.85
2111,LENALIDOMID ZENTIVA in Kombination mit Ixazomib und Dexamethason,21381.09,KOMBI_CROSS,ind_part .09 from 18541.09,0.85
2112,LENALIDOMID-TEVA in Kombination mit Ixazomib und Dexamethason,21379.09,KOMBI_CROSS,ind_part .09 from 18541.09,0.85
2158,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",21024.02,PIPE_PART_CROSS,ind_part .02 from 19016.02,0.9
2160,Nicht-kleinzelliges Lungenkarzinom (NSCLC),19520.07,PIPE_PART_MATCH,same dossier 19520,0.95
2172,KYPROLIS in Kombination mit Dexamethason (Kd),20481.04,PIPE_PART_MATCH,same dossier 20481,0.95
2173,KYPROLIS in Kombination mit Daratumumab und Dexamethason (KDd),20481.02,PIPE_PART_MATCH,same dossier 20481,0.95
2178,Vitiligo Erwachsene und Jugendliche ab 12 Jahren,21819.01,PIPE_PART_MATCH,same dossier 21819,0.95
2199,"Behandlung von Erwachsenen, Kindern und Jugendlichen mit atypischem Hämolytisch-Urämischen Syndrom (aHUS)",21024.02,PIPE_PART_CROSS,ind_part .02 from 19016.02,0.9
2210,POMALIDOMID ACCORD in Kombination mit Daratumumab und Dexamethason (2L+),22005.03,KOMBI_CROSS,ind_part .03 from 20221.03,0.85
2211,POMALIDOMID ACCORD in Kombination mit Isatuximab und Dexamethason,22005.04,KOMBI_CROSS,ind_part .04 from 20221.04,0.85
2226,HERCEPTIN in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,17354.01,PIPE_PART_MATCH,same dossier 17354,0.95
2227,HERZUMA in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21304.01,PIPE_PART_MATCH,same dossier 21304,0.95
2230,KANJINTI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21018.01,PIPE_PART_MATCH,same dossier 21018,0.95
2244,LENALIDOMID SANDOZ in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21312.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
2247,LENALIDOMID SPIRIG HC in Kombination mit DARZALEX / DARZALEX SC und Dexamethason (2L+),21384.12,KOMBI_CROSS,ind_part .12 from 18541.12,0.85
2252,Kombination LENALIDOMID-TEVA und Tafasitamab,21379.11,KOMBI_CROSS,ind_part .11 from 18541.11,0.85
2261,OGIVRI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21087.01,PIPE_PART_MATCH,same dossier 21087,0.95
2262,OGIVRI in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,21109.01,PIPE_PART_CROSS,ind_part .01 from 21087.01,0.9
2309,TRAZIMERA in Kombination mit Pertuzumab (PERJETA) als adjuvante Therapie des Mammakarzinoms,20966.01,PIPE_PART_MATCH,same dossier 20966,0.95
2326,Melanom Kombinationstherapie,19520.02,PIPE_PART_MATCH,same dossier 19520,0.95
2327,Nierenzellkarzinom (RCC),19520.03,PIPE_PART_MATCH,same dossier 19520,0.95
2328,Kolorektales Karzinom (CRC) mit dMMR/MSI-H,19520.04,PIPE_PART_MATCH,same dossier 19520,0.95
2329,Ösophageales Plattenepithelkarzinom (OSCC),19520.05,PIPE_PART_MATCH,same dossier 19520,0.95
2330,Malignes pleurales Mesotheliom (MPM),19520.06,PIPE_PART_MATCH,same dossier 19520,0.95
2334,Kombinationstherapie mit Lynparza (Olaparib),21090.08,PIPE_PART_MATCH,same dossier 21090,0.95
2338,ZIRABEV in Kombination mit Atezolizumab (TECENTRIQ) zur Behandlung des inoperablen oder metastasierten hepatozellulären Karzinoms (HCC),21090.09,PIPE_PART_MATCH,same dossier 21090,0.95
2348,Gewichtsregulierung Erwachsene:,21593.02,PIPE_PART_MATCH,same dossier 21593,0.95
2350,Gewichtsregulierung Erwachsene:,21977.02,PIPE_PART_MATCH,same dossier 21977,0.95
887,Kombination LENALIDOMID ACCORD und Tafasitamab,21398.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
888,Kombination LENALIDOMID BMS und Tafasitamab,21377.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
889,Kombination LENALIDOMID DEVATIS und Tafasitamab,21420.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
890,Kombination LENALIDOMID SANDOZ und Tafasitamab,21312.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
891,Kombination LENALIDOMID SPIRIG HC und Tafasitamab,21384.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
892,Kombination LENALIDOMID ZENTIVA und Tafasitamab,21381.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
960,Kombination DECITABIN ACCORD und Venetoclax,21554.01,BRAND_CROSS,ind_part .01 from 21512.01,0.85
1284,Kombination LENALIDOMID Viatris und Tafasitamab,21626.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1356,Kombination LENALIDOMID ACCORD und Tafasitamab,21398.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1358,Kombination LENALIDOMID BMS und Tafasitamab,21377.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1360,Kombination LENALIDOMID DEVATIS und Tafasitamab,21420.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1362,Kombination LENALIDOMID SANDOZ und Tafasitamab,21312.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1364,Kombination LENALIDOMID SPIRIG HC und Tafasitamab,21384.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1366,Kombination LENALIDOMID VIATRIS und Tafasitamab,21626.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1368,Kombination LENALIDOMID ZENTIVA und Tafasitamab,21381.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1747,Kombination LENALIDOMID ACCORD und Tafasitamab,21398.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1750,Kombination LENALIDOMID BMS und Tafasitamab,21377.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1754,Kombination LENALIDOMID DEVATIS und Tafasitamab,21420.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1757,Kombination LENALIDOMID SANDOZ und Tafasitamab,21312.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1760,Kombination LENALIDOMID SPIRIG HC und Tafasitamab,21384.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1766,Kombination LENALIDOMID ZENTIVA und Tafasitamab,21381.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1789,"Kombination POMALIDOMID SANDOZ, Elotuzumab und Dexamethason",21773.01,BRAND_CROSS,ind_part .01 from 20221.01,0.85
1810,"Kombination POMALIDOMID ZENTIVA, Elotuzumab und Dexamethason",21806.01,BRAND_CROSS,ind_part .01 from 20221.01,0.85
1816,"Kombination POMALIDOMID SPIRIG HC, Elotuzumab und Dexamethason",21805.01,BRAND_CROSS,ind_part .01 from 20221.01,0.85
1838,Kombination DECITABIN ACCORD und Venetoclax,21554.01,BRAND_CROSS,ind_part .01 from 21512.01,0.85
1874,Kombination DECITABIN IDEOGEN und Venetoclax,21846.01,BRAND_CROSS,ind_part .01 from 21512.01,0.85
1897,Kombination LENALIDOMID ACCORD und Tafasitamab,21398.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1898,Kombination LENALIDOMID BMS und Tafasitamab,21377.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1899,Kombination LENALIDOMID DEVATIS und Tafasitamab,21420.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1900,Kombination LENALIDOMID SANDOZ und Tafasitamab,21312.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1901,Kombination LENALIDOMID SPIRIG HC und Tafasitamab,21384.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1902,Kombination LENALIDOMID VIATRIS und Tafasitamab,21626.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
1903,Kombination LENALIDOMID ZENTIVA und Tafasitamab,21381.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
2110,Kombination LENALIDOMID ZENTIVA und Tafasitamab,21381.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
2209,"Kombination POMALIDOMID ACCORD, Elotuzumab und Dexamethason",22005.01,BRAND_CROSS,ind_part .01 from 20221.01,0.85
2237,Kombination LENALIDOMID ACCORD und Tafasitamab,21398.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
2239,Kombination LENALIDOMID BMS und Tafasitamab,21377.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
2241,Kombination LENALIDOMID DEVATIS und Tafasitamab,21420.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
2243,Kombination LENALIDOMID SANDOZ und Tafasitamab,21312.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
2246,Kombination LENALIDOMID SPIRIG HC und Tafasitamab,21384.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
2249,Kombination LENALIDOMID VIATRIS und Tafasitamab,21626.11,BRAND_CROSS,ind_part .11 from 18541.11,0.85
86,Renale Anämie bei Niereninsuffizienz.,17807.01,FUZZY_MATCHED,Renale Anämie bei Niereninsuffizienz: 17807.1,0.9024390243902439
87,Myelodysplastisches Syndrom der Risikogruppen low oder intermediate-1:,17807.02,FUZZY_MATCHED,Myelodysplastisches Syndrom der Risikogruppen low oder intermediate-1: 17807.3,0.9387755102040817
253,Myelodysplastisches Syndrom der Risikogruppen low oder intermediate-1:,17807.02,FUZZY_MATCHED,Myelodysplastisches Syndrom der Risikogruppen low oder intermediate-1: 17807.3,0.9387755102040817
395,"Morbus Waldenström (MW, Mono- und Kombinationstherapie)",21011.06,FUZZY_MATCHED,"Morbus Waldenström (MW, Kombinationstherapie)",0.9
454,DARZALEX SC in Kombination mit Pomalidomid und Dexamethason,21150.06,FUZZY_MATCHED,DARZALEX SC in Kombination mit Pomalidomid und Dexamethason (2L+),0.9516129032258065
603,Darzalex in Kombination mit Carfilzomib und Dexamethason (KDd),20589.07,FUZZY_MATCHED,DARZALEX in Kombination mit Carfilzomib und Dexamethason (2L+),0.9516129032258065
604,Darzalex in Kombination mit Carfilzomib und Dexamethason (KDd),21150.07,FUZZY_MATCHED,DARZALEX SC in Kombination mit Carfilzomib und Dexamethason (2L+),0.9291338582677166
886,IMNOVID in Kombination mit Daratumumab und Dexamethason,20221.03,FUZZY_MATCHED,IMNOVID in Kombination mit Daratumumab und Dexamethason (2L+),0.9482758620689655
11,Follikuläres Lymphom (FL),20248.xx,SINGLE_SEGMENT_CODE,only code for lim 372,1.0
22,Melanom,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 476,1.0
24,2L NSCLC,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 478,1.0
25,Melanom,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 479,1.0
27,2L NSCLC,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 481,1.0
31,Follikuläres Lymphom (FL),20248.xx,SINGLE_SEGMENT_CODE,only code for lim 1023,1.0
32,Melanom,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 1025,1.0
34,2L NSCLC,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 1027,1.0
43,Melanom,20461.xx,SINGLE_SEGMENT_CODE,only code for lim 1046,1.0
44,Melanom,20461.xx,SINGLE_SEGMENT_CODE,only code for lim 1047,1.0
46,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN),20461.xx,SINGLE_SEGMENT_CODE,only code for lim 1049,1.0
47,Klassisches Hodgkin-Lymphom (cHL),20461.xx,SINGLE_SEGMENT_CODE,only code for lim 1050,1.0
48,Metastasierter Brustkrebs (mBC),19972.xx,SINGLE_SEGMENT_CODE,only code for lim 1059,1.0
50,Melanom,20461.xx,SINGLE_SEGMENT_CODE,only code for lim 1075,1.0
51,Melanom,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 1085,1.0
53,2L NSCLC,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 1087,1.0
54,Klassisches Hodgkin Lymphom,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 1088,1.0
55,Urothelkarzinom,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 1089,1.0
56,Erstlinienbehandlung,20594.xx,SINGLE_SEGMENT_CODE,only code for lim 1095,1.0
57,Zweit- oder Drittlinienbehandlung,20594.xx,SINGLE_SEGMENT_CODE,only code for lim 1096,1.0
72,Melanom,20461.xx,SINGLE_SEGMENT_CODE,only code for lim 1152,1.0
74,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN),20461.xx,SINGLE_SEGMENT_CODE,only code for lim 1154,1.0
75,Klassisches Hodgkin-Lymphom (cHL),20461.xx,SINGLE_SEGMENT_CODE,only code for lim 1155,1.0
88,Renale Anämie bei Niereninsuffizienz.,19007.xx,SINGLE_SEGMENT_CODE,only code for lim 1216,1.0
89,Renale Anämie bei Niereninsuffizienz.,15497.xx,SINGLE_SEGMENT_CODE,only code for lim 1220,1.0
92,Renale Anämie bei Niereninsuffizienz.,17227.xx,SINGLE_SEGMENT_CODE,only code for lim 1227,1.0
93,Rheumatoide Arthritis:,20037.xx,SINGLE_SEGMENT_CODE,only code for lim 1268,1.0
100,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H,20461.xx,SINGLE_SEGMENT_CODE,only code for lim 1407,1.0
104,"Kombination REVLIMID, Bortezomib und Dexamethason (Induktion vor Stammzelltransplantation)",18541.xx,SINGLE_SEGMENT_CODE,only code for lim 1421,1.0
105,"Kombination REVLIMID, Bortezomib und Dexamethason (ohne Stammzelltransplantation)",18541.xx,SINGLE_SEGMENT_CODE,only code for lim 1422,1.0
111,Rheumatoide Arthritis (RA),20240.xx,SINGLE_SEGMENT_CODE,only code for lim 1489,1.0
112,Polyartikuläre juvenile idiopathische Arthritis (pJIA),20240.xx,SINGLE_SEGMENT_CODE,only code for lim 1490,1.0
113,Systemische juvenile idiopathische Arthritis (sJIA),20240.xx,SINGLE_SEGMENT_CODE,only code for lim 1491,1.0
114,Rheumatoide Arthritis (RA),20893.xx,SINGLE_SEGMENT_CODE,only code for lim 1492,1.0
115,Polyartikuläre juvenile idiopathische Arthritis (pJIA),20893.xx,SINGLE_SEGMENT_CODE,only code for lim 1493,1.0
116,Systemische juvenile idiopathische Arthritis (sJIA),20893.xx,SINGLE_SEGMENT_CODE,only code for lim 1494,1.0
117,Klassisches Hodgkin Lymphom,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 1514,1.0
178,Typ 2 Diabetes,20270.xx,SINGLE_SEGMENT_CODE,only code for lim 1721,1.0
179,Herzinsuffizienz,20270.xx,SINGLE_SEGMENT_CODE,only code for lim 1722,1.0
185,Rheumatoide Arthritis:,19845.xx,SINGLE_SEGMENT_CODE,only code for lim 1758,1.0
188,Rheumatoide Arthritis:,20724.xx,SINGLE_SEGMENT_CODE,only code for lim 1760,1.0
201,Klassisches Hodgkin-Lymphom (Monotherapie) KN087,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 1803,1.0
203,1L plattenepitheliales NSCLC (in Kombination mit Carboplatin und Paclitaxel) bei Patienten mit TPS < 50% KN407,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 1805,1.0
204,1L nicht-plattenepitheliales NSCLC (in Kombination mit Pemetrexed und Platin-Chemotherapie) bei Patienten mit TPS < 50% KN189,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 1806,1.0
217,Rheumatoide Arthritis:,20037.xx,SINGLE_SEGMENT_CODE,only code for lim 1828,1.0
218,1L nicht-plattenepitheliales NSCLC (in Kombination mit Pemetrexed und Platin-Chemotherapie) bei Patienten mit TPS < 50% KN189,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 1864,1.0
219,Erhaltungstherapie nach autologer Stammzelltransplantation,18541.04,SINGLE_SEGMENT_CODE,only code for lim 1874,1.0
220,"Kombination REVLIMID, Bortezomib und Dexamethason (Induktion vor Stammzelltransplantation)",18541.05,SINGLE_SEGMENT_CODE,only code for lim 1875,1.0
221,"Kombination REVLIMID, Bortezomib und Dexamethason (ohne Stammzelltransplantation)",18541.06,SINGLE_SEGMENT_CODE,only code for lim 1876,1.0
222,"Kombination REVLIMID, Carfilzomib und Dexamethason",18541.07,SINGLE_SEGMENT_CODE,only code for lim 1877,1.0
224,"Kombination REVLIMID, lxazomib und Dexamethason",18541.09,SINGLE_SEGMENT_CODE,only code for lim 1879,1.0
225,"Kombination REVLIMID, Daratumumab und Dexamethason",18541.10,SINGLE_SEGMENT_CODE,only code for lim 1880,1.0
247,Rheumatoide Arthritis,20636.xx,SINGLE_SEGMENT_CODE,only code for lim 1915,1.0
248,Atopische Dermatitis,20636.xx,SINGLE_SEGMENT_CODE,only code for lim 1916,1.0
297,Asthma,20819.xx,SINGLE_SEGMENT_CODE,only code for lim 2014,1.0
323,1L nicht-plattenepitheliales NSCLC (in Kombination mit Pemetrexed und Platin-Chemotherapie) bei Patienten mit TPS < 50% KN189,20416.xx,SINGLE_SEGMENT_CODE,only code for lim 2027,1.0
373,Asthma,21258.xx,SINGLE_SEGMENT_CODE,only code for lim 2062,1.0
377,Melanom,20461.03,SINGLE_SEGMENT_CODE,only code for lim 2076,1.0
382,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN),20461.05,SINGLE_SEGMENT_CODE,only code for lim 2083,1.0
383,Klassisches Hodgkin-Lymphom (cHL),20461.06,SINGLE_SEGMENT_CODE,only code for lim 2084,1.0
384,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H,20461.08,SINGLE_SEGMENT_CODE,only code for lim 2085,1.0
385,Morbus Behçet,20374.xx,SINGLE_SEGMENT_CODE,only code for lim 2086,1.0
386,Rheumatoide Arthritis,21028.xx,SINGLE_SEGMENT_CODE,only code for lim 2092,1.0
388,Ankylosierende Spondylitis (Morbus Bechterew),21028.xx,SINGLE_SEGMENT_CODE,only code for lim 2094,1.0
391,Erstlinienbehandlung,20594.01,SINGLE_SEGMENT_CODE,only code for lim 2111,1.0
392,Zweit- oder Drittlinienbehandlung,20594.02,SINGLE_SEGMENT_CODE,only code for lim 2112,1.0
397,Melanom,20461.03,SINGLE_SEGMENT_CODE,only code for lim 2124,1.0
401,Klassisches Hodgkin-Lymphom (cHL),20461.06,SINGLE_SEGMENT_CODE,only code for lim 2128,1.0
402,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H,20461.08,SINGLE_SEGMENT_CODE,only code for lim 2129,1.0
403,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant,20461.09,SINGLE_SEGMENT_CODE,only code for lim 2130,1.0
410,Melanom,20461.03,SINGLE_SEGMENT_CODE,only code for lim 2160,1.0
416,Plattenepithelkarzinom im Kopf-Hals-Bereich (SCCHN),20461.05,SINGLE_SEGMENT_CODE,only code for lim 2165,1.0
417,Klassisches Hodgkin-Lymphom (cHL),20461.06,SINGLE_SEGMENT_CODE,only code for lim 2166,1.0
418,Kolorektales Karzinom (CRC) mit dMMR/ MSI-H,20461.08,SINGLE_SEGMENT_CODE,only code for lim 2167,1.0
419,Ösophaguskarzinom oder Karzinom des gastroösophagealen Übergangs (OC oder GEJC) adjuvant,20461.09,SINGLE_SEGMENT_CODE,only code for lim 2168,1.0
433,Atopische Dermatitis,21028.xx,SINGLE_SEGMENT_CODE,only code for lim 2202,1.0
449,Daratumumab in Kombination mit Bortezomib und Dexamethason,20589.05,SINGLE_SEGMENT_CODE,only code for lim 2216,1.0
453,Daratumumab in Kombination mit Bortezomib und Dexamethason,20589.05,SINGLE_SEGMENT_CODE,only code for lim 2220,1.0
455,IMNOVID in Kombination mit Daratumuab und Dexamethason,20221.03,SINGLE_SEGMENT_CODE,only code for lim 2225,1.0
458,"Kombination LENALIDOMID BMS, Bortezomib und Dexamethason (Induktion vor Stammzelltransplantation)",21377.05,SINGLE_SEGMENT_CODE,only code for lim 2229,1.0
459,"Kombination LENALIDOMID BMS, Bortezomib und Dexamethason (ohne Stammzelltransplantation)",21377.06,SINGLE_SEGMENT_CODE,only code for lim 2230,1.0
460,Erhaltungstherapie nach autologer Stammzelltransplantation,21377.04,SINGLE_SEGMENT_CODE,only code for lim 2231,1.0
461,"Kombination LENALIDOMID BMS, Carfilzomib und Dexamethason",21377.07,SINGLE_SEGMENT_CODE,only code for lim 2232,1.0
462,"Kombination LENALIDOMID BMS, Elotuzumab und Dexamethason",21377.08,SINGLE_SEGMENT_CODE,only code for lim 2233,1.0
463,"Kombination LENALIDOMID BMS, lxazomib und Dexamethason",21377.09,SINGLE_SEGMENT_CODE,only code for lim 2234,1.0
464,"Kombination LENALIDOMID BMS, Daratumumab und Dexamethason",21377.10,SINGLE_SEGMENT_CODE,only code for lim 2235,1.0
465,"Kombination LENALIDOMID SANDOZ, Bortezomib und Dexamethason (Induktion vor Stammzelltransplantation)",21312.05,SINGLE_SEGMENT_CODE,only code for lim 2237,1.0
466,"Kombination LENALIDOMID SANDOZ, Bortezomib und Dexamethason (ohne Stammzelltransplantation)",21312.06,SINGLE_SEGMENT_CODE,only code for lim 2238,1.0
467,Erhaltungstherapie nach autologer Stammzelltransplantation,21312.04,SINGLE_SEGMENT_CODE,only code for lim 2239,1.0
468,"Kombination LENALIDOMID SANDOZ, Carfilzomib und Dexamethason",21312.07,SINGLE_SEGMENT_CODE,only code for lim 2240,1.0
469,"Kombination LENALIDOMID SANDOZ, Elotuzumab und Dexamethason",21312.08,SINGLE_SEGMENT_CODE,only code for lim 2241,1.0
470,"Kombination LENALIDOMID SANDOZ, lxazomib und Dexamethason",21312.09,SINGLE_SEGMENT_CODE,only code for lim 2242,1.0
471,"Kombination LENALIDOMID SANDOZ, Daratumumab und Dexamethason",21312.10,SINGLE_SEGMENT_CODE,only code for lim 2243,1.0
472,Erhaltungstherapie nach autologer Stammzelltransplantation,21384.04,SINGLE_SEGMENT_CODE,only code for lim 2245,1.0
473,"Kombination LENALIDOMID Spirig, Carfilzomib und Dexamethason",21384.07,SINGLE_SEGMENT_CODE,only code for lim 2246,1.0
474,"Kombination LENALIDOMID Spirig, Elotuzumab und Dexamethason",21384.08,SINGLE_SEGMENT_CODE,only code for lim 2247,1.0
475,"Kombination LENALIDOMID Spirig, lxazomib und Dexamethason",21384.09,SINGLE_SEGMENT_CODE,only code for lim 2248,1.0
476,"Kombination LENALIDOMID Spirig, Daratumumab und Dexamethason",21384.10,SINGLE_SEGMENT_CODE,only code for lim 2249,1.0
477,"Kombination LENALIDOMID-TEVA, Bortezomib und Dexamethason (Induktion vor Stammzelltransplantation)",21379.05,SINGLE_SEGMENT_CODE,only code for lim 2251,1.0
478,"Kombination LENALIDOMID-TEVA, Bortezomib und Dexamethason (ohne Stammzelltransplantation)",21379.06,SINGLE_SEGMENT_CODE,only code for lim 2252,1.0
479,Erhaltungstherapie nach autologer Stammzelltransplantation,21379.04,SINGLE_SEGMENT_CODE,only code for lim 2253,1.0
480,"Kombination LENALIDOMID-TEVA, Carfilzomib und Dexamethason",21379.07,SINGLE_SEGMENT_CODE,only code for lim 2254,1.0
482,"Kombination LENALIDOMID-TEVA, lxazomib und Dexamethason",21379.09,SINGLE_SEGMENT_CODE,only code for lim 2256,1.0
483,"Kombination LENALIDOMID-TEVA, Daratumumab und Dexamethason",21379.10,SINGLE_SEGMENT_CODE,only code for lim 2257,1.0
516,"Kombination LENALIDOMID ACCORD, Bortezomib und Dexamethason (Induktion vor Stammzelltransplantation)",21398.05,SINGLE_SEGMENT_CODE,only code for lim 2296,1.0
517,"Kombination LENALIDOMID ACCORD, Bortezomib und Dexamethason (ohne Stammzelltransplantation)",21398.06,SINGLE_SEGMENT_CODE,only code for lim 2297,1.0
518,Erhaltungstherapie nach autologer Stammzelltransplantation,21398.04,SINGLE_SEGMENT_CODE,only code for lim 2298,1.0
519,"Kombination LENALIDOMID ACCORD, Carfilzomib und Dexamethason",21398.07,SINGLE_SEGMENT_CODE,only code for lim 2299,1.0
520,"Kombination LENALIDOMID ACCORD, Elotuzumab und Dexamethason",21398.08,SINGLE_SEGMENT_CODE,only code for lim 2300,1.0
521,"Kombination LENALIDOMID ACCORD, lxazomib und Dexamethason",21398.09,SINGLE_SEGMENT_CODE,only code for lim 2301,1.0
522,"Kombination LENALIDOMID ACCORD, Daratumumab und Dexamethason",21398.10,SINGLE_SEGMENT_CODE,only code for lim 2302,1.0
523,"Kombination LENALIDOMID BMS, Elotuzumab und Dexamethason",21377.08,SINGLE_SEGMENT_CODE,only code for lim 2303,1.0
524,"Kombination LENALIDOMID SANDOZ, Elotuzumab und Dexamethason",21312.08,SINGLE_SEGMENT_CODE,only code for lim 2304,1.0
525,"Kombination LENALIDOMID Spirig, Elotuzumab und Dexamethason",21384.08,SINGLE_SEGMENT_CODE,only code for lim 2305,1.0
527,"Kombination LENALIDOMID ZENTIVA, Carfilzomib und Dexamethason",21381.07,SINGLE_SEGMENT_CODE,only code for lim 2308,1.0
528,"Kombination LENALIDOMID ZENTIVA, Elotuzumab und Dexamethason",21381.08,SINGLE_SEGMENT_CODE,only code for lim 2309,1.0
529,"Kombination LENALIDOMID ZENTIVA, lxazomib und Dexamethason",21381.09,SINGLE_SEGMENT_CODE,only code for lim 2310,1.0
530,"Kombination LENALIDOMID ZENTIVA, Daratumumab und Dexamethason",21381.10,SINGLE_SEGMENT_CODE,only code for lim 2311,1.0
569,Herzinsuffizienz,20244.xx,SINGLE_SEGMENT_CODE,only code for lim 2379,1.0
570,"Kombination LENALIDOMID DEVATIS, Bortezomib und Dexamethason (Induktion vor Stammzelltransplantation)",21420.05,SINGLE_SEGMENT_CODE,only code for lim 2384,1.0
571,"Kombination LENALIDOMID DEVATIS, Bortezomib und Dexamethason (ohne Stammzelltransplantation)",21420.06,SINGLE_SEGMENT_CODE,only code for lim 2385,1.0
572,Erhaltungstherapie nach autologer Stammzelltransplantation,21420.04,SINGLE_SEGMENT_CODE,only code for lim 2386,1.0
573,"Kombination LENALIDOMID DEVATIS, Carfilzomib und Dexamethason",21420.07,SINGLE_SEGMENT_CODE,only code for lim 2387,1.0
574,"Kombination LENALIDOMID DEVATIS, Elotuzumab und Dexamethason",21420.08,SINGLE_SEGMENT_CODE,only code for lim 2388,1.0
575,"Kombination LENALIDOMID DEVATIS, lxazomib und Dexamethason",21420.09,SINGLE_SEGMENT_CODE,only code for lim 2389,1.0
576,"Kombination LENALIDOMID DEVATIS, Daratumumab und Dexamethason",21420.10,SINGLE_SEGMENT_CODE,only code for lim 2390,1.0
596,Atopische Dermatitis,21343.xx,SINGLE_SEGMENT_CODE,only code for lim 2445,1.0
608,"Kombination LENALIDOMID ACCORD, Ixazomib und Dexamethason",21398.09,SINGLE_SEGMENT_CODE,only code for lim 2478,1.0
609,"Kombination LENALIDOMID BMS, Ixazomib und Dexamethason",21377.09,SINGLE_SEGMENT_CODE,only code for lim 2479,1.0
610,"Kombination LENALIDOMID DEVATIS, Ixazomib und Dexamethason",21420.09,SINGLE_SEGMENT_CODE,only code for lim 2480,1.0
611,"Kombination LENALIDOMID SANDOZ, Ixazomib und Dexamethason",21312.09,SINGLE_SEGMENT_CODE,only code for lim 2481,1.0
612,"Kombination LENALIDOMID Spirig, Ixazomib und Dexamethason",21384.09,SINGLE_SEGMENT_CODE,only code for lim 2482,1.0
613,"Kombination LENALIDOMID ZENTIVA, Ixazomib und Dexamethason",21381.09,SINGLE_SEGMENT_CODE,only code for lim 2483,1.0
641,Kombination VIDAZA und Venetoclax,18384.01,SINGLE_SEGMENT_CODE,only code for lim 2516,1.0
796,"Kombination LENALIDOMID Spirig, Bortezomib und Dexamethason (Induktion vor Stammzelltransplantation)",21384.05,SINGLE_SEGMENT_CODE,only code for lim 2594,1.0
797,"Kombination LENALIDOMID Spirig, Bortezomib und Dexamethason (ohne Stammzelltransplantation)",21384.06,SINGLE_SEGMENT_CODE,only code for lim 2595,1.0
817,"Kombination LENALIDOMID ZENTIVA, Bortezomib und Dexamethason (Induktion vor Stammzelltransplantation)",21381.05,SINGLE_SEGMENT_CODE,only code for lim 2640,1.0
818,"Kombination LENALIDOMID ZENTIVA, Bortezomib und Dexamethason (ohne Stammzelltransplantation)",21381.06,SINGLE_SEGMENT_CODE,only code for lim 2641,1.0
819,Erhaltungstherapie nach autologer Stammzelltransplantation,21381.04,SINGLE_SEGMENT_CODE,only code for lim 2642,1.0
820,"Kombination LENALIDOMID ZENTIVA, Carfilzomib und Dexamethason",21381.07,SINGLE_SEGMENT_CODE,only code for lim 2643,1.0
841,Herzinsuffizienz,20270.xx,SINGLE_SEGMENT_CODE,only code for lim 2667,1.0
842,Chronische Nierenerkrankung,20270.xx,SINGLE_SEGMENT_CODE,only code for lim 2668,1.0
849,IMNOVID in Kombination mit Daratumuab und Dexamethason,20221.03,SINGLE_SEGMENT_CODE,only code for lim 2671,1.0
850,"Kombination REVLIMID, Bortezomib und Dexamethason (ohne Stammzelltransplantation)",18541.06,SINGLE_SEGMENT_CODE,only code for lim 2677,1.0
851,Erhaltungstherapie nach autologer Stammzelltransplantation,18541.04,SINGLE_SEGMENT_CODE,only code for lim 2678,1.0
852,"Kombination REVLIMID, Carfilzomib und Dexamethason",18541.07,SINGLE_SEGMENT_CODE,only code for lim 2679,1.0
855,"Kombination REVLIMID, Daratumumab und Dexamethason",18541.10,SINGLE_SEGMENT_CODE,only code for lim 2682,1.0
856,Kombination VIDAZA und Venetoclax,18384.01,SINGLE_SEGMENT_CODE,only code for lim 2687,1.0
857,Nicht-kleinzelliges Bronchialkarzinom,21100.01,SINGLE_SEGMENT_CODE,only code for lim 2716,1.0
858,Kutanes Plattenepithelkarzinom,21100.02,SINGLE_SEGMENT_CODE,only code for lim 2717,1.0
859,CTEPH:,20163.xx,SINGLE_SEGMENT_CODE,only code for lim 2734,1.0
860,PAH:,20163.xx,SINGLE_SEGMENT_CODE,only code for lim 2735,1.0
867,Kombination AZACITIDIN ACCORD und Venetoclax,20876.01,SINGLE_SEGMENT_CODE,only code for lim 2744,1.0
868,Kombination AZACITIDIN IDEOGEN und Venetoclax,21414.01,SINGLE_SEGMENT_CODE,only code for lim 2745,1.0
869,Kombination AZACITIDIN MYLAN und Venetoclax,21235.01,SINGLE_SEGMENT_CODE,only code for lim 2746,1.0
870,Kombination AZACITIDIN SANDOZ und Venetoclax,21123.01,SINGLE_SEGMENT_CODE,only code for lim 2747,1.0
871,Kombination AZACITIDIN SPIRIG HC und Venetoclax,21234.01,SINGLE_SEGMENT_CODE,only code for lim 2748,1.0
1111,Chronisch obstruktive Lungenerkrankung (COPD),21023.xx,SINGLE_SEGMENT_CODE,only code for lim 2951,1.0
1112,Asthma,21023.xx,SINGLE_SEGMENT_CODE,only code for lim 2952,1.0
1188,Typ 2 Diabetes,20244.xx,SINGLE_SEGMENT_CODE,only code for lim 3033,1.0
1189,Herzinsuffizienz (HFrEF),20244.xx,SINGLE_SEGMENT_CODE,only code for lim 3034,1.0
1212,Kombination RIXATHON mit POLIVY und Bendamustin bei rezidiviertem oder refraktärem diffusem grosszelligem B-Zell-Lymphom (DLBCL),20820.03,SINGLE_SEGMENT_CODE,only code for lim 3080,1.0
1215,Kombination TRUXIMA mit POLIVY und Bendamustin bei rezidiviertem oder refraktärem diffusem grosszelligem B-Zell-Lymphom (DLBCL),20815.03,SINGLE_SEGMENT_CODE,only code for lim 3090,1.0
1260,Herzinsuffizienz mit reduzierter Ejektionsfraktion (HFrEF),20244.xx,SINGLE_SEGMENT_CODE,only code for lim 3188,1.0
1261,Herzinsuffizienz  mit erhaltener oder mittlerer Ejektionsfraktion (HFpEF / HFmEF),20244.xx,SINGLE_SEGMENT_CODE,only code for lim 3189,1.0
1287,"ALK-positives fortgeschrittenes, nicht-kleinzelliges Lungenkarzinom (NSCLC)",19861.xx,SINGLE_SEGMENT_CODE,only code for lim 3250,1.0
1288,"ROS1-positives fortgeschrittenes, nicht-kleinzelliges Lungenkarzinom (NSCLC)",19861.xx,SINGLE_SEGMENT_CODE,only code for lim 3251,1.0
1289,Rheumatoide Arthritis (nur 5 mg Dosierung):,20037.01,SINGLE_SEGMENT_CODE,only code for lim 3253,1.0
1290,Colitis ulcerosa (Dosierungen 5 mg und 10 mg):,20037.02,SINGLE_SEGMENT_CODE,only code for lim 3254,1.0
1291,Psoriasis Arthritis (nur 5 mg Dosierung):,20037.03,SINGLE_SEGMENT_CODE,only code for lim 3255,1.0
1292,Ankylosierende Spondylitis (nur 5 mg Dosierung):,20037.04,SINGLE_SEGMENT_CODE,only code for lim 3256,1.0
1293,"2L+ chronisch lymphatische Leukämie (CLL, Monotherapie)",21365.01,SINGLE_SEGMENT_CODE,only code for lim 3267,1.0
1295,Herzinsuffizienz mit reduzierter Ejektionsfraktion (HFrEF),20270.xx,SINGLE_SEGMENT_CODE,only code for lim 3269,1.0
1296,Herzinsuffizienz mit erhaltener oder mittlerer Ejektionsfraktion (HFpEF / HFmEF),20270.xx,SINGLE_SEGMENT_CODE,only code for lim 3270,1.0
1299,Kombination AZACITIDIN VIATRIS und Venetoclax,21235.01,SINGLE_SEGMENT_CODE,only code for lim 3276,1.0
1310,Für alle Indikationen gilt:,21028.xx,SINGLE_SEGMENT_CODE,only code for lim 3300,1.0
1311,Rheumatoide Arthritis,21028.01,SINGLE_SEGMENT_CODE,only code for lim 3301,1.0
1313,Ankylosierende Spondylitis (Morbus Bechterew),21028.03,SINGLE_SEGMENT_CODE,only code for lim 3303,1.0
1314,Atopische Dermatitis,21028.04,SINGLE_SEGMENT_CODE,only code for lim 3304,1.0
1326,Systemischer Lupus erythematodes (SLE),19903.xx,SINGLE_SEGMENT_CODE,only code for lim 3317,1.0
1327,Lupusnephritis (LN),19903.xx,SINGLE_SEGMENT_CODE,only code for lim 3318,1.0
1328,Systemischer Lupus erythematodes (SLE),20822.xx,SINGLE_SEGMENT_CODE,only code for lim 3320,1.0
1329,Lupusnephritis (LN),20822.xx,SINGLE_SEGMENT_CODE,only code for lim 3321,1.0
1331,Cryopyrin-assoziiertes periodisches Syndrom (CAPS):,19119.01,SINGLE_SEGMENT_CODE,only code for lim 3331,1.0
1332,Aktive systemische juvenile idiopathische Arthritis (sJIA):,19119.02,SINGLE_SEGMENT_CODE,only code for lim 3332,1.0
1373,IPF,20362.xx,SINGLE_SEGMENT_CODE,only code for lim 3419,1.0
1374,PF-ILD,20362.xx,SINGLE_SEGMENT_CODE,only code for lim 3420,1.0
1375,SSc-ILD,20362.xx,SINGLE_SEGMENT_CODE,only code for lim 3421,1.0
1388,Patienten mit Hämophilie B mit Hemmkörpern,21692.02,SINGLE_SEGMENT_CODE,only code for lim 3446,1.0
1405,Herzinsuffizienz mit reduzierter Ejektionsfraktion (HFrEF),20415.xx,SINGLE_SEGMENT_CODE,only code for lim 3488,1.0
1455,Austausch Referenzpräparat/Biosimilar,21264.xx,SINGLE_SEGMENT_CODE,only code for lim 3518,1.0
1600,Austausch Referenzpräparat/Biosimilar,21084.xx,SINGLE_SEGMENT_CODE,only code for lim 3557,1.0
1603,Für alle Indikationen gilt:,20636.xx,SINGLE_SEGMENT_CODE,only code for lim 3561,1.0
1604,Rheumatoide Arthritis,20636.01,SINGLE_SEGMENT_CODE,only code for lim 3562,1.0
1605,Atopische Dermatitis,20636.02,SINGLE_SEGMENT_CODE,only code for lim 3563,1.0
1606,Austausch Referenzpräparat/Biosimilar,19296.xx,SINGLE_SEGMENT_CODE,only code for lim 3564,1.0
1607,Austausch Referenzpräparat/Biosimilar,20850.xx,SINGLE_SEGMENT_CODE,only code for lim 3565,1.0
1608,Austausch Referenzpräparat/Biosimilar,21272.xx,SINGLE_SEGMENT_CODE,only code for lim 3566,1.0
1624,Austausch Referenzpräparat/Biosimilar,20820.xx,SINGLE_SEGMENT_CODE,only code for lim 3572,1.0
1627,Austausch Referenzpräparat/Biosimilar,20815.xx,SINGLE_SEGMENT_CODE,only code for lim 3580,1.0
1628,Austausch Referenzpräparat/Biosimilar,21617.xx,SINGLE_SEGMENT_CODE,only code for lim 3582,1.0
1647,Austausch Referenzpräparat/Biosimilar,21090.xx,SINGLE_SEGMENT_CODE,only code for lim 3586,1.0
1687,Kombination AZACITIDIN STADA und Venetoclax,21759.01,SINGLE_SEGMENT_CODE,only code for lim 3593,1.0
1689,Aktive Psoriasis-Arthritis,20311.xx,SINGLE_SEGMENT_CODE,only code for lim 3598,1.0
1690,Juvenile idiopathische Arthritis (JIA) (nur 75 mg und 150 mg),20311.xx,SINGLE_SEGMENT_CODE,only code for lim 3599,1.0
1691,Aktive mittelschwere bis schwere Hidradenitis suppurativa (HS) / Acne inversa,20311.xx,SINGLE_SEGMENT_CODE,only code for lim 3600,1.0
1692,Aktive ankylosierende Spondylitis / Morbus Bechterew (nur 150 mg),20311.xx,SINGLE_SEGMENT_CODE,only code for lim 3601,1.0
1693,Aktive mittelschwere bis schwere Hidradenitis suppurativa (HS) / Acne inversa,20311.xx,SINGLE_SEGMENT_CODE,only code for lim 3602,1.0
1695,Aktive Psoriasis-Arthritis,20311.xx,SINGLE_SEGMENT_CODE,only code for lim 3604,1.0
1696,Aktive ankylosierende Spondylitis / Morbus Bechterew (nur 150 mg),20311.xx,SINGLE_SEGMENT_CODE,only code for lim 3605,1.0
1697,Juvenile idiopathische Arthritis (JIA) (nur 75 mg und 150 mg),20311.xx,SINGLE_SEGMENT_CODE,only code for lim 3606,1.0
1698,Aktive mittelschwere bis schwere Hidradenitis suppurativa (HS) / Acne inversa,20316.xx,SINGLE_SEGMENT_CODE,only code for lim 3607,1.0
1700,Aktive Psoriasis-Arthritis,20316.xx,SINGLE_SEGMENT_CODE,only code for lim 3609,1.0
1701,Aktive ankylosierende Spondylitis / Morbus Bechterew (nur 150 mg),20316.xx,SINGLE_SEGMENT_CODE,only code for lim 3610,1.0
1702,Juvenile idiopathische Arthritis (JIA) (nur 75 mg und 150 mg),20316.xx,SINGLE_SEGMENT_CODE,only code for lim 3611,1.0
1704,Aktive Psoriasis-Arthritis,21385.xx,SINGLE_SEGMENT_CODE,only code for lim 3613,1.0
1705,Aktive mittelschwere bis schwere Hidradenitis suppurativa (HS) / Acne inversa,21385.xx,SINGLE_SEGMENT_CODE,only code for lim 3614,1.0
1772,Austausch Referenzpräparat/Biosimilar,21272.xx,SINGLE_SEGMENT_CODE,only code for lim 3666,1.0
1785,Atopische Dermatitis - Erwachsene,21367.xx,SINGLE_SEGMENT_CODE,only code for lim 3682,1.0
1827,Kombination AZACITIDIN ACCORD und Venetoclax,20876.01,SINGLE_SEGMENT_CODE,only code for lim 3807,1.0
1828,Kombination AZACITIDIN MYLAN und Venetoclax,21235.01,SINGLE_SEGMENT_CODE,only code for lim 3809,1.0
1829,Kombination AZACITIDIN SANDOZ und Venetoclax,21123.01,SINGLE_SEGMENT_CODE,only code for lim 3810,1.0
1830,Kombination AZACITIDIN SPIRIG HC und Venetoclax,21234.01,SINGLE_SEGMENT_CODE,only code for lim 3811,1.0
1831,Kombination AZACITIDIN STADA und Venetoclax,21759.01,SINGLE_SEGMENT_CODE,only code for lim 3812,1.0
1832,Kombination AZACITIDIN VIATRIS und Venetoclax,21235.01,SINGLE_SEGMENT_CODE,only code for lim 3813,1.0
1866,Für alle Indikationen gilt:,21028.xx,SINGLE_SEGMENT_CODE,only code for lim 3887,1.0
1867,Rheumatoide Arthritis (nur 15 mg Dosisstärke),21028.01,SINGLE_SEGMENT_CODE,only code for lim 3888,1.0
1868,Psoriasis-Arthritis (nur 15 mg Dosisstärke),21028.02,SINGLE_SEGMENT_CODE,only code for lim 3889,1.0
1869,Ankylosierende Spondylitis (Morbus Bechterew) ) (nur 15 mg Dosisstärke),21028.03,SINGLE_SEGMENT_CODE,only code for lim 3890,1.0
1870,Atopische Dermatitis (nur 15 mg Dosisstärke),21028.04,SINGLE_SEGMENT_CODE,only code for lim 3891,1.0
1871,"Morbus Crohn (15 mg, 30 mg, 45 mg Dosisstärke)",21028.05,SINGLE_SEGMENT_CODE,only code for lim 3892,1.0
1872,"Colitis Ulcerosa (15 mg, 30 mg, 45 mg Dosisstärke)",21028.06,SINGLE_SEGMENT_CODE,only code for lim 3893,1.0
1873,Behandlung von lokal fortgeschrittenem oder metastasiertem NSCLC,20594.xx,SINGLE_SEGMENT_CODE,only code for lim 3921,1.0
1875,Nicht-kleinzelliges Bronchialkarzinom,21100.01,SINGLE_SEGMENT_CODE,only code for lim 3935,1.0
1876,Kutanes Plattenepithelkarzinom,21100.02,SINGLE_SEGMENT_CODE,only code for lim 3936,1.0
1894,Atopische Dermatitis – Erwachsene und Jugendliche ab 12 Jahren,21813.xx,SINGLE_SEGMENT_CODE,only code for lim 3971,1.0
1895,Atopische Dermatitis – Erwachsene und Jugendliche ab 12 Jahren,21849.xx,SINGLE_SEGMENT_CODE,only code for lim 3972,1.0
1913,Renale Anämie bei Niereninsuffizienz.,17227.xx,SINGLE_SEGMENT_CODE,only code for lim 3999,1.0
1946,Austausch Referenzpräparat/Biosimilar,21862.xx,SINGLE_SEGMENT_CODE,only code for lim 4089,1.0
1982,Herzinsuffizienz  mit erhaltener oder mittlerer Ejektionsfraktion (HFpEF / HFmEF),20244.xx,SINGLE_SEGMENT_CODE,only code for lim 4125,1.0
1983,Chronische Nierenerkrankung,20244.xx,SINGLE_SEGMENT_CODE,only code for lim 4126,1.0
2065,Jugendliche:,21548.xx,SINGLE_SEGMENT_CODE,only code for lim 4297,1.0
2116,Atopische Dermatitis – Erwachsene und Jugendliche ab 12 Jahren,21912.xx,SINGLE_SEGMENT_CODE,only code for lim 4360,1.0
2122,Patienten mit Hämophilie B mit Hemmkörpern,21692.02,SINGLE_SEGMENT_CODE,only code for lim 4376,1.0
2142,Induktionstherapie,20844.xx,SINGLE_SEGMENT_CODE,only code for lim 4410,1.0
2143,Erhaltungstherapie,20844.xx,SINGLE_SEGMENT_CODE,only code for lim 4411,1.0
2144,Folgende Bedingungen gelten für beide Indikationen,20844.xx,SINGLE_SEGMENT_CODE,only code for lim 4412,1.0
2153,Morbus Behçet,20374.xx,SINGLE_SEGMENT_CODE,only code for lim 4426,1.0
2159,Jugendliche:,21548.xx,SINGLE_SEGMENT_CODE,only code for lim 4443,1.0
2161,"2L+ chronisch lymphatische Leukämie (CLL, Monotherapie)",21365.01,SINGLE_SEGMENT_CODE,only code for lim 4453,1.0
2168,Pädiatrische Patienten (12 bis 17 Jahre),19992.xx,SINGLE_SEGMENT_CODE,only code for lim 4466,1.0
2170,Typ 2 Diabetes,20244.xx,SINGLE_SEGMENT_CODE,only code for lim 4472,1.0
2202,Maternale Impfung zum passiven Schutz von Säuglingen,21821.xx,SINGLE_SEGMENT_CODE,only code for lim 4531,1.0
2206,mHSPC,21068.xx,SINGLE_SEGMENT_CODE,only code for lim 4542,1.0
2207,mHSPC in Kombination mit Docetaxel,21068.xx,SINGLE_SEGMENT_CODE,only code for lim 4543,1.0
2222,Chronisch obstruktive Lungenerkrankung (COPD),21925.xx,SINGLE_SEGMENT_CODE,only code for lim 4561,1.0
2238,LENALIDOMID ACCORD in Kombination mit Isatuximab und Bortezomib und Dexamethason,21398.14,SINGLE_SEGMENT_CODE,only code for lim 4594,1.0
2240,"LENALIDOMID BMS in Kombination mit Isatuximab, Bortezomib und Dexamethason (Isa-VRd)",21377.14,SINGLE_SEGMENT_CODE,only code for lim 4596,1.0
2242,LENALIDOMID DEVATIS in Kombination mit Isatuximab und Bortezomib und Dexamethason,21420.14,SINGLE_SEGMENT_CODE,only code for lim 4598,1.0
2245,LENALIDOMID SANDOZ in Kombination mit Isatuximab und Bortezomib und Dexamethason),21312.14,SINGLE_SEGMENT_CODE,only code for lim 4601,1.0
2248,LENALIDOMID SPIRIG HC in Kombination mit Isatuximab und Bortezomib und Dexamethason,21384.14,SINGLE_SEGMENT_CODE,only code for lim 4604,1.0
2250,LENALIDOMID VIATRIS in Kombination mit Isatuximab und Bortezomib und Dexamethason,21626.14,SINGLE_SEGMENT_CODE,only code for lim 4606,1.0
2251,LENALIDOMID ZENTIVA in Kombination mit Isatuximab und Bortezomib und Dexamethason,21381.14,SINGLE_SEGMENT_CODE,only code for lim 4607,1.0
2253,LENALIDOMID-TEVA in Kombination mit Isatuximab und Bortezomib und Dexamethason,21379.14,SINGLE_SEGMENT_CODE,only code for lim 4609,1.0
2294,Jugendliche:,20574.xx,SINGLE_SEGMENT_CODE,only code for lim 4673,1.0
2306,Rheumatoide Arthritis (nur 5 mg Dosierung):,22021.01,SINGLE_SEGMENT_CODE,only code for lim 4692,1.0
2307,Colitis ulcerosa (Dosierungen 5 mg und 10 mg):,22021.02,SINGLE_SEGMENT_CODE,only code for lim 4693,1.0
2308,Psoriasis Arthritis (nur 5 mg Dosierung):,22021.03,SINGLE_SEGMENT_CODE,only code for lim 4694,1.0
2345,Typ 2 Diabetes,20270.xx,SINGLE_SEGMENT_CODE,only code for lim 4752,1.0
2346,Typ 2 Diabetes,20270.xx,SINGLE_SEGMENT_CODE,only code for lim 4753,1.0
2351,IPF,22033.xx,SINGLE_SEGMENT_CODE,only code for lim 4761,1.0
2352,PF-ILD,22033.xx,SINGLE_SEGMENT_CODE,only code for lim 4762,1.0
2353,SSc-ILD,22033.xx,SINGLE_SEGMENT_CODE,only code for lim 4763,1.0
2354,IPF,22044.xx,SINGLE_SEGMENT_CODE,only code for lim 4764,1.0
2355,PF-ILD,22044.xx,SINGLE_SEGMENT_CODE,only code for lim 4765,1.0
2356,SSc-ILD,22044.xx,SINGLE_SEGMENT_CODE,only code for lim 4766,1.0
2357,IPF,22031.xx,SINGLE_SEGMENT_CODE,only code for lim 4767,1.0
2358,PF-ILD,22031.xx,SINGLE_SEGMENT_CODE,only code for lim 4768,1.0
2359,SSc-ILD,22031.xx,SINGLE_SEGMENT_CODE,only code for lim 4769,1.0
2360,IPF,22035.xx,SINGLE_SEGMENT_CODE,only code for lim 4770,1.0
2361,PF-ILD,22035.xx,SINGLE_SEGMENT_CODE,only code for lim 4771,1.0
2362,SSc-ILD,22035.xx,SINGLE_SEGMENT_CODE,only code for lim 4772,1.0
2365,Colitis ulcerosa (Dosierungen 5 mg und 10 mg):,22021.02,SINGLE_SEGMENT_CODE,only code for lim 4780,1.0
412,Melanom,20461.02,ORDINAL_POSITION,position 0 of 2 in lim 2162,0.8
413,Melanom,20461.03,ORDINAL_POSITION,position 1 of 2 in lim 2162,0.8
